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Chapter 1
             
Introduction
Type 1 diabetes is a T-cell mediated auto-immune disease. Its pathogenesis has 
not yet completely been elucidated, but factors such as environmental triggers, 
genetic susceptibility, different age-dependent auto-immune responses, be-
ta-cell subtypes more susceptible for inflammation, and certain viral infections 
are assumed to be involved in the process leading to diabetes (1). The incidence 
of type 1 diabetes is still increasing in childhood and adolescence (2-4), the 
largest increase being observed in the youngest age-group (age 0-4 years) (2, 
3). From a lifetime perspective, diagnosis of type 1 diabetes at a younger age will 
result in longer disease duration, which has been convincingly demonstrated to 
be one of the major risk factors for the development of the micro- and macro-
vascular complications of diabetes: neuropathy, nephropathy, retinopathy and 
premature cardiovascular disease (5-9)(Table 1).  
 
Table 1: Established risk factors for the development of micro- and macrovascular complications
Younger age at onset of diabetes* (10, 11)
Puberty (10, 12, 13)
Smoking (5, 14)
Gender** (7, 15-17)
Hypertension (5, 14)
Dyslipidemia (17, 18)
The presence of microvascular complications  (5, 7, 14, 16, 19)
Increased BMI (14, 17, 20)
*    The effect of young age at onset of diabetes has not consistently been described (10, 11) 
**  Gender may be of variable influence, depending on the complication studied (7, 15-17)
An increase in these complications is therefore expected to occur. However, 
whereas diabetes duration is a non-modifiable risk factor associated with com-
plications, there are modifiable risk factors (16, 21-32), poor glycaemic control 
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(6-8, 16, 21, 22, 33-35) being the most important one. Improvement of glycaemic 
control has been shown to prevent or delay the development of these complica-
tions (7, 22, 35, 36). Controversially, despite improvements in glycaemic control 
over the last decades, the prevalence and incidence of micro- and macrovascular 
complications in patients with type 1 diabetes is still alarmingly high in both adults 
(6, 22, 33, 37-39) and adolescents (35, 40). As these complications are not only 
associated with decreased quality of life but also with reduced life expectancy 
up to 10 years (7, 15, 19), the challenge of present diabetes care is to improve this 
still unfavourable lifetime perspective in patients with type 1 diabetes. In our 
opinion, early and appropriate risk stratification is an important step towards 
this challenge. Appropriate risk stratification, i.e. identifying children and ado-
lescents with type 1 diabetes that have one or more risk factor(s) and identifying 
those that already have early signs of micro- and/or macrovascular complications 
(Figure 1), may facilitate more individualized patient care. This will in turn allow 
both personalised screening protocols for the presence of other risk factors and 
complications and the initiation of intervention where possible.  
 
Figure 1: Illustration of the current liftetime perspective of one patient in red. The expected change in life-
time perspective, based on an alarming result of a surrogate marker described in this thesis, is shown in blue. 
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General introduction
Terminology: 
Risk factor: each determinant in a determinant-endpoint relationship Surrogate marker: a substitute for a 
clinical endpoint which is associated with that endpoint or prognostic of that endpoint Early sign of  
complication: preclinical and/or clinical abnormality that may progress to a complication, i.e. endpoint 
Complication: clinical condition with medical /personal consequences and requiring treatment and/or 
medication and/or intensive follow-up
The general objective of this thesis is to improve this risk stratification in children 
and adolescents with type 1 diabetes, aiming to fill a scientific gap by studying 
some underexposed complication fields in pediatrics. In section 1.2 and Appendix 
1 we review what was known in the literature in 2007 on tests in these fields that 
were not included in the current guidelines at the time (41). Literature from 2007 
on other fields is outside the scope of this thesis but is discussed in Appendix 1. In 
section 1.3 we describe the research questions of the ‘Early Detection of Diabetes 
Damage in Youth and Search for early prevention’ (EDDDY-S) study, which was 
based on this review.
 
1.2 Risk factors and potential markers for micro- 
and macrovascular complications studied in the  
EDDDY-S study 
Two tests for diabetic peripheral neuropathy (DPN)
In 2007, the ISPAD guideline recommended the performance of history taking, 
physical examination and (optional) the measurement of the nerve conduction 
velocity by electrophysiologic study as screening tests for DPN (41). These tests 
were assumed to detect clinical DPN or, in case of abnormal nerve conduction 
velocity (NCV) only, to detect subclinical DPN. In daily practise, history taking 
and physical examination were performed.
Electrophysiologic studies, including NCV of sensory and motor nerves and sen-
sory action potential (SNAP) amplitude, measure the function of large myelinat-
ed nerve fibers. In 2007, the diagnostic value of these electrophysiologic studies 
for the detection of subclinical DPN in children and adolescents with type 1 dia-
betes was debated (43). Besides, earlier detection of subclinical DPN by focus on 
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unmyelinated small fiber nerve dysfunction (assumed to precede dysfunction of 
the large myelinated nerve fibers) and more focus on axonal damage (assumed to 
precede myelin damage) was subject of debate as well (43-45). However, at that 
time, there was only a paucity of studies investigating damage of small unmyelin-
ated nerve fibers in adults with type 1 diabetes and there were only few studies 
that focussed on other measures of dysfunction of the large myelinated nerve 
fibers than the conventional test of electrophysiologic study (13, 43, 45-50). 
 
Figure 2: ISPAD Clinical Practice Consensus Guidelines 2006-2007. Microvascular and macrovascular 
complications. Pediatr Diabetes. 2007;8(3):163-70.
 Neurological examination: history taking and physical examination.  
        When to commence screening is unclear. 
     Lipid profile: LDL-C, HDL-C, triglycerides after the age of 12 years. 
  AER/ACR or first morning albumin concentration from the age of 11 years with 2 years of  
        diabetes duration and from the age of 9 years with 5 years of diabetes duration 
  Fundal photography or mydriatic ophthalmoscopy from the age of 11 years with 2 years of  
         diabetes duration and from the age of 9 years with 5 years of diabetes duration  
    Blood pressure annually  
     Three monthly: HbA1c, BMI
0 1 2 3 4 5
Three monthly: HbA1c, BMI
Neurological examination: history taking and physical examina-
tion. When to commence screening is unclear.
Fundal photography or mydriatic ophthalmoscopy from the age of
 11 years with 2 years of diabetes duration and from the age of 9 years
 with 5 years of diabetes duration 
Blood pressure annually 
AER/ACR or first morning albumin concentration from the age of
 11 years with 2 years of diabetes duration and from the age of 9 years
 with 5 years of diabetes duration
years
diagnosis:
type 1 diabetes
Lipid profile: LDL-C, HDL-C, triglycerides after the age of 
12 years.
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Carotid intima media thickness (cIMT)
The 2007 ISPAD guideline recommended screening for the presence of risk fac-
tors for macrovascular complications (41). These recommendations lack assess-
ment of any surrogate marker for macrovascular disease. By 2007, measurement 
of carotid intima media thickness (cIMT), endothelial dysfunction and arterial 
stiffness, were suggested to be surrogate markers for macrovascular disease in 
type 1 diabetes (51-53). Of these, most studies were on cIMT. 
Atherosclerosis leads to premature cardiovascular disease (54) and was shown 
to develop, among others, in the carotid intima (55). Hyperglycaemia was found 
as one of the risk factors for atherosclerosis and increased cIMT (56-58). Indeed, 
increased cIMT had been found in adult patients with type 1 diabetes compared 
with healthy controls (52). In children and adolescents with type 1 diabetes, most, 
but not all, studies found an increased cIMT in the patients as compared with 
healthy controls (11, 59-62)
Summary of the pathophysiology of type 1 diabetes-related  
micro- and macrovascular  complications 
 
Over the last decades it has become apparent from several clinical studies (e.g DCCT and UKPDS) 
and preclinical observations that although diabetic complications in specific tissues may result from 
several pathological processes, hyperglycaemia is involved in most complications. Accompanied 
by glycaemic variability, hyperglycaemia is considered to be the central metabolic insult on tissues, 
resulting in activation of common pathways in vulnerable tissues. Aetiological co-factors including 
smoking, ageing, hyperinsulinaemia, dyslipidaemia and hypertension amplify this response. These 
common pathways include advanced glycation end products (AGEs) formation, reactive oxygen 
species overproduction, protein kinase C activation, mitochondrial dysfunction and activation of 
pro-inflammatory and pro-fibrotic signalling cascades and cytokines, causing the characteristic 
pathological and clinical abnormalities. Studies have shown that pathways resulting in diabetic 
complications are self-perpetuating once activated by the ‘glycaemic insults’. Epigenetic changes 
and influences on microRNA expression patterns have been mentioned as potential mechanisms. 
Microvascular complications affect small vessels of the retina, kidney and nerves, with compli-
cations resulting from impaired autoregulation of blood flow, altered permeability, inflammation, 
extracellular matrix accumulation, hypoxia, cell loss, neovascularisation and fibrosis. Macrovascular 
complications result from arterial endothelial and smooth muscle inflammation and dysfunction 
leading to accelerated atherosclerosis, with resultant ischaemic heart disease, cerebrovascular 
disease and peripheral vascular disease (36, 39, 42).
14
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Longitudinal lipid dynamics
The ISPAD guideline (41) advised annual screening for the risk factor hyperten-
sion and screening every 5 years for the risk factor dyslipidemia from the age of 12 
years onwards. It also included target levels for body mass index (BMI), smoking 
behaviour and other known risk factors for macrovascular disease such as HbA1c. 
By 2007, two large longitudinal studies had determined the prevalence of dyslip-
idemia and lipid dynamics throughout childhood and adolescence. Prevalence 
was found to be high. Moreover, a considerable number of patients were found 
to change their lipid level already throughout childhood and adolescence from a 
low-risk lipid level to a less favourable one (63, 64). 
Advanced glycation end products (AGEs) in skin
AGEs are products of reactive oxygen species and non-enzymatic reactions 
between sugars and amino groups of proteins (‘Maillard reaction’) (65, 66). Their 
production is enhanced in patients with higher glucose levels and other sac-
charide derivatives (67-69). Local accumulation of AGEs causes, among others, 
structural alteration of long-lived proteins such as collagen, fibrinogen and myelin 
through the formation of intermolecular and intramolecular cross-links (67-69). 
Associations between elevated AGEs and development of micro- and macrovas-
cular complications in type 1 and type 2 diabetes were described in adults (68-71). 
Altogether, (elevated) AGEs may thus be a surrogate marker for the develop-
ment of these micro- and macrovascular complications. Quantification of AGEs 
has been studied by measurement of serum levels of certain AGEs (72, 73), by 
measurement of collagen glycation by means of determining the plantar fascia 
thickness in children and adolescents (74) or by skin autofluorescence (SAF) in 
adults only (71, 75).
15
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1.3 Research questions of the EDDDY-S study
In the design of the EDDDY-S study, we considered that any test to be studied 
in the pediatric age group should not only meet standard criteria to be suitable 
as (future) screening test (76), but should also be feasible for use in daily patient 
care, i.e. preferably being non-invasive, minimally time-consuming, and easy to 
perform. Furthermore, we aimed to fill a scientific gap by studying some under-
exposed areas in complication-related research in pediatrics and in the ISPAD 
consensus guideline of 2007 (Figure 2). Consequently the EDDDY-S study did 
not cover tests in all fields of complications, but focused on three main areas 
(Figure 3).
Two tests for diabetic peripheral neuropathy (DPN) 
Tests for the detection of subclinical DPN were found to be missing in the 2007 
ISPAD guideline (41). 
Hence we formulated research question 1: 
what is the diagnostic value of measuring various compound muscle action po-
tential (CMAP) scan variables, including measures of axonal excitability, axonal 
loss and reinnervation of the peroneal nerve by CMAP scan in children and ado-
lescents with type 1 diabetes for the assessment of subclinical DPN? (Chapter 2) 
Research question 2:
assesses the diagnostic value of measurement of the sensory nerve conduction 
velocity (NCV) and sensory nerve action potential (SNAP) amplitude of two 
distal sensory nerves in children and adolescents with type 1 diabetes for the 
assessment of subclinical DPN. (Chapter 3) 
A response to the letter of Malik et al. was added, highlighting the importance of 
focussing on small nerve fiber function. (Chapter 4)
Carotid intima media thickness (cIMT)
The 2007 ISPAD guideline (41) did not include a surrogate marker(s) for macro-
vascular complications. 
16
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Figure 3: Promising tests studying some underexposed areas in complication-related research in pediatric 
diabetes and selected tests in these areas for the EDDDY-S study.
• cIMT
• endothelial dysfunction measures
• arterial stiff ness measures
• extension of the serum lipid profi le
• longitudinal information lipid profi le
• serum, plantar fascia and skin AGEs
• myelinated and unmyelinated FD by 
sural nerve biopsy
• IENFD by skin biopsy
• CNFD by corneal confocal microscopy
• amplitude and/or NCV of motor peri-
pheral nerves
• electrophysiologic measures dorsal sural 
nerve
•  cIMT
•  longitudinal infor mation
lipid profi le
y
• CMAP scan measures 
• SNAP/NCV of sensory nerves
• AGEs by skin autofl uorescence
Abbrevations
FD: fi ber density 
IENFD: intraepidermal nerve fi ber density
CNFD: corneal nerve fi ber density
NCV: nerve conduction velocity
cIMT: carotid intima media thickness
AGEs: advanced glycation endproducts
EDDDY-S: Early Detection of Diabetes Damage in Youth and Search for early prevention
CMAP: compound muscle action potential
SNAP: sensory nerve action potential
EDDDY-S study  designed in 2007
NeuropathyMacro-
vascular
Additional
 risk factorsand surrogate markers
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Hence we formulated research question 3: 
is the intima-media thickness of the carotid artery (cIMT) in children and adoles-
cents with type 1 diabetes increased when compared with age- and gender-strat-
ified healthy controls and what are the risk factors for increased cIMT in type 1 
diabetes patients? (Chapter 5)
Longitudinal lipid dynamics
The EDDDY-S study also focussed on a more accurate insight in lipid dynamics, 
because studies in 2007 showed a considerable number of children and adoles-
cents with type 1 diabetes to have the risk factor dyslipidemia. 
We felt that the attention for this and its implications should be increased 
and formulated research question 4:  
do many children and adolescents with type 1 diabetes change lipid levels to an 
unfavourable level (‘lose track of lipids’) already through childhood and ado-
lescence? If so, what is an appropriate screening interval for timely detection of 
these patients and can a prognostic index including concomitant measurement 
of the determinants HbA1c, age, gender, BMI, ethnicity and diabetes duration 
predict which patients lose track of lipids on the short term? (Chapter 6)
Advanced glycation end products (AGEs) in skin 
We found that skin autofluorescence, a presumed surrogate marker for micro- 
and macrovascular complications, was not included in the 2007 ISPAD guideline 
(Figure 2). 
This led to research question 5: 
is skin autofluorescence (SAF) in children and adolescents with type 1 diabetes 
increased when compared with age and gender-stratified healthy controls and 
what are the risk factors for increased SAF in the type 1 diabetes patients? (Chap-
ter 7) 
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Abstract
Objective
The compound muscle action potential (CMAP) scan is a novel neurophysiologi-
cal technique that appears more sensitive in detecting peripheral motor neuropa-
thy than conventional methods. This study explores the value of the CMAP scan 
for the detection of subclinical diabetic peripheral motor neuropathy.
Methods
In this cross-sectional pilot study, CMAP scanning of the peroneal nerve was 
performed in a) 13 well-controlled patients (8-25 years old) with type 1 diabetes 
mellitus (T1DM) duration between 2.5 and 5 years, b) 17 patients (10-25 years old) 
with a duration of T1DM of at least 10 years, poorly controlled and/or with micro-
vascular complications and c) 13 adults with T1DM and established clinical dia-
betic peripheral neuropathy. Various CMAP scan variables, including measures 
of axonal excitability and axonal loss and reinnervation, were compared between 
patients and healthy controls.
Results
Axonal excitability was significantly decreased in the young patient groups as 
compared with their controls. The CMAP scan measures of axonal loss and rein-
nervation differed only between patients with clinical diabetic peripheral neurop-
athy and their controls.
Conclusion
Motor nerve axonal excitability seems to be reduced early in T1DM, even in 
well-controlled young patients, and probably before (irreversible) axonal damage 
occurs. These changes can be measured by the CMAP scan, which makes this a 
promising tool for detecting nerve dysfunction in T1DM. 
Introduction
Diabetic peripheral neuropathy (DPN) is a frequent complication in patients 
with type 1 diabetes mellitus (T1DM) (1, 2). Previous studies have shown that 
subclinical DPN already exists in children and teens with T1DM (3, 4), and that 
its incidence in this age group is increasing (5). An appropriate screening tool 
targeted at this age group is of paramount importance since glycemic control is a 
modifiable risk factor for DPN that may prevent ongoing nerve damage (1, 2, 6).
Presently, there is no established methodology to detect subclinical DPN in 
young patients (3, 4). The clinical benefit of the frequently applied nerve con-
duction studies of both motor and sensory nerves is an issue of ongoing debate 
(7, 8). Moreover, several papers suggest a different vulnerability and/or underly-
ing pathophysiology for motor and sensory nerves (9-12). Nerve function should 
therefore be evaluated for motor and sensory nerves separately. 
A frequently used measure in motor nerve conduction studies is the maximal 
compound muscle action potential (CMAP) amplitude of the extensor digito-
rum brevis (EDB) muscle (2, 13). A decreased CMAP amplitude is considered to 
indicate the loss of (functioning) peroneal nerve axons innervating the muscle 
fibers of the EDB. In the early stage of a neurogenic process, reinnervation of 
denervated muscle fibers by axonal sprouts of remaining intact axons results in 
normalization of the maximum CMAP amplitude (14). Therefore, patients with 
(an early stage of) subclinical DPN are unlikely to show an abnormal maximum 
CMAP amplitude, whereas more direct estimates of axonal loss and/or dysfunc-
tion may be valuable indicators of early nerve damage (14). This is supported by 
animal models of T1DM showing that an increased motor unit size and decreased 
motor unit number can be identified early in the disease course of DPN (11, 15). 
In these studies, the maximum CMAP amplitude remained unchanged (15) or 
changed later in the course of the disease (11). 
The recently developed CMAP scan, basically a high-resolution stimulus-re-
sponse curve, provides a visual and quantitative impression of the build-up of a 
muscle in terms of motor unit size and motor unit number (14, 16, 17). Further-
more, by evaluation of the stimulus intensities (SIs) applied, the CMAP scan can 
be used to assess the axonal excitability of the investigated motor nerve (16, 17). 
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Alterations in axonal excitability may precede axonal damage and loss, and may, 
therefore, be an even better marker of subclinical DPN than motor unit size and 
motor unit number (11, 18). The CMAP scan has a good reproducibility (19) and 
although it requires application of a large number of stimuli, the predictable, re-
petitive nature of the stimulus pattern and the mostly low intensities ensure that 
the technique is well-tolerated (20).
We hypothesized that the joint assessment of maximum CMAP amplitude, 
axonal excitability, motor unit size and motor unit loss by means of this CMAP 
scan can be used to identify pathological motor nerve changes typical for DPN 
in an early stage. In this pilot study, we performed CMAP scans in two groups of 
young patients with T1DM as well as in a group of adult patients with T1DM, with 
the three groups representing three degrees of DPN severity. In addition, CMAP 
scans were performed in healthy controls.
Patients and Methods 
Patients and clinical measurements
For the purpose of the present study, we would preferably compare the results 
of the CMAP scan between T1DM patients with and without subclinical DPN 
and between these patients and patients with clinical DPN (as positive controls). 
Because the presence or absence of subclinical DPN cannot be established 
reliably by means of measurements other than biopsies (which we considered too 
invasive and hence unethical considering the pilot nature of the present study) 
(7, 8), we used sets of strict inclusion criteria related to established risk factors 
for DPN to define three groups of patients that were most likely to represent the 
three conditions (1, 6).
Included in the first patient group were patients, who were 8-25 years old, with a 
disease duration of 2.5-5 years and a haemoglobin A1c (HbA1c)(Vantage system, 
Siemens Medical Solutions Diagnostics, Tarrytown, NY) below 64 mmol/mol 
(8%) since the time of diagnosis (21). Eligible for the second group were patients, 
aged 10-25 years, who met the following criteria: I) disease duration of 10 years 
or more, II) evidence for poor glycemic control, e.g. at least three HbA1c levels 
above 69 mmol/mol (8.5%) between 2006 and 2009, and/or III) presence of 
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(early) signs of microvascular complications, e.g. retinopathy or microalbuminuria 
(22). All patients of the two forementioned groups were without clinical DPN, 
defined as: I) numbness of the feet and/or burning pain in the legs or feet, and 
II) reduced vibration sensation (determined with a 128-Hz tuning fork), and/or a 
decreased tactile perception threshold (defined as the inability to sense the 5.07 
Semmes-Weinstein monofilament). Previous work suggests that the presence of 
subclinical DPN is unlikely in patients that meet the above criteria for inclusion in 
the first group (1, 6). Patients that were included in this group were called P1-pa-
tients. By contrast, subclinical DPN might be expected in at least some patients 
of the second group. These patients were called P2-patients. The third group 
included patients aged 20-70 years who were diagnosed with clinical symptoms 
of DPN according to the definition of DPN as described above (P3-patients). 
The P1- and P2-patients were matched to age with a maximum age difference 
of 3.5 years with healthy controls (C1-controls and C2-controls). The controls of 
P3-patients were included from an existing cohort of healthy adult controls and 
were matched to age with a maximum difference of 3.17 years (C3-controls). Pa-
tients and controls had to be euthyroid and they had to have a negative medical 
history for renal failure and diseases known to cause peripheral neuropathy.
The P1- and P2-patients attended the outpatient clinic of Diabeter, a specialized 
pediatric and adolescent diabetes center in Rotterdam, the Netherlands. The 
(adult) P3-patients attended the Internal Medicine outpatient clinic of either the 
St. Franciscus Gasthuis or the Erasmus Medical Centre in Rotterdam, the Neth-
erlands. The patients received medical care in agreement with the International 
Society for Pediatric and Adolescent Diabetes and American Diabetes Associa-
tion guidelines (22, 23). Retrospective chart review was performed to obtain data 
on the exact disease duration and the most recently measured HbA1c. 
The study was performed in agreement with the Declaration of Helsinki and ap-
proved by the Medical Ethical Board of the Erasmus MC Rotterdam. All subjects 
participated after signed informed consent.
Neurophysiological measurements
The CMAP scan is a non-invasive electrophysiological tool which records the 
electrical activity of a muscle in response to repetitive transcutaneous stimula-
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tion of the motor nerve. Each axon (and related motor unit) has its own threshold 
for stimulation and will be activated when the stimulus intensity (SI) exceeds this 
threshold. When the SI is gradually increased from subthreshold to supramaximal 
values, all motor units in the muscle are successively activated. 
CMAP scan recordings were performed from the EDB muscle using a Nicolet 
Viking Select EMG system (CareFusion, San Diego, CA) with the novel CMAP 
scan utility, as previously described (16, 20). The active recording electrode was 
placed over the belly of the EDB, at the point where the negative peak amplitude 
of the CMAP was maximal. The reference electrode was placed over the meta-
tarsophalangeal joint of the fifth phalanx. Stimulation was applied approximately 
8 cm proximal to the active recording electrode. After determination of the SI at 
which the lowest-threshold motor unit was activated (S0) and of the lowest SI 
that could elicit the maximum CMAP (S100), the CMAP scan was performed by 
decreasing the SI gradually from S100 to S0 of, in total, 500 consecutive stimuli (2 
Hz, 0.1 ms pulse duration). 
Plotting the recorded CMAP amplitude against the corresponding SI resulted in 
a stimulus-response curve, the so-called CMAP scan. In healthy subjects, the 
CMAP scan is usually smooth and sigmoid (Figure 1A and 1C). When large motor 
units are present, these tend to be visible as so-called “steps” (Figure 1B and 1D). 
These steps provide information on the extent of collateral reinnervation as well 
as an indication of motor unit loss (16, 17). 
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Figure 1: CMAP scan stimulus-response curve of a healthy subject and a patient
Figure 1A: CMAP scan obtained from a healthy subject: the stimulus-response curve is smooth and 
sigmoid. Figure 1B: CMAP scan obtained from a patient with clinical diabetic peripheral neuropathy: the 
stimulus-response curve is interrupted by large gaps and shifted toward abnormally high stimulus 
intensities, reflecting motor unit loss, the presence of enlarged motor unit potentials, and a reduced axonal 
excitability.  Figure 1C and D: The same stimulus-response curves as in 1A and 1B, but now plotted on the 
same scale to allow direct visual comparison of the differences in maximum CMAP amplitude (y-axis) and 
stimulus intensities (x-axis) between control and patient. 
 
CMAP scan data analysis 
Data were imported in MATLAB (version R2008a; The MathWorks, Natick, 
MA). From each CMAP scan, we derived the SIs required to generate 5, 50, and 
95 percent of the maximal CMAP amplitude (S5, S50, and S95, respectively). S5 
and S95 provide an indication of the excitability of the most excitable and least 
excitable axons, respectively, whereas S50 provides an average value. As quanti-
tative indicators of axonal loss and reinnervation, we used the maximum CMAP 
amplitude and the variable D50. D50 represents the number of size-ordered 
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gaps in the CMAP scan (starting with the largest one present) that need to be 
summed to exceed 50% of the maximal CMAP amplitude. For this purpose, a gap 
is defined as the difference between consecutive (sorted) CMAP sizes. That is, 
a CMAP scan resulting from 500 stimuli is built up from 499 gaps. In the hypo-
thetical case that all gaps were equal, D50 would be 250 because 250 of these 
equal-sized gaps need to be summed to add up to (and just exceed) 50% of the 
maximum CMAP. In the presence of reinnervation, large motor units will con-
tribute large motor unit potentials to the CMAP scan, resulting in large gaps. As a 
consequence, D50 will decline.
Statistical analyses
The patient and control group characteristics were described as proportions, me-
dians, and interquartile ranges (IQR). The Mann-Whitney U test was used to test 
differences between two groups with skewed variables. In case of missing data, 
patients and their matched controls were excluded for that comparison. The sig-
nificance level was set to p=0.05 (two-sided). All analyses were performed with 
SPSS version 17.0 for Windows (SPSS Inc, Chicago, Illinois).
Results
Our strict inclusion criteria for the P1- and P2-patient groups resulted in a limited 
number of patients that were eligible for participation in this study (30 out of 
500 outpatients screened, n=13 in the group of P1-patients and n=17 in the group 
of P2-patients). Thirteen patients were eligible for the P3-group. Three young 
patients (two P2-patients and one P1-patient) and two P3-patients withdrew 
from the study after informed consent. One P2-patient and one P1-patient had 
to be excluded because of incomplete data. Table 1 shows the characteristics of 
the remaining patients and controls. P3-patients had a significantly longer disease 
duration than P2- and P1-patients (both p<0.01). The HbA1c of the P3-patients 
was similar to that of the P1-group. 
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Table 1: Characteristics of patients and controls
P1- 
patients
P2- 
patients
P3- 
patients
C1- 
controls
C2- 
controls
C3- 
controls
n= 11 14 11 11 14 11
Sex M/F 6/5 5/9 7/4 5/6 7/7 5/6
Age (yr) 13.92(12.58-17.08)
18.75
(15.92-
22.42)
47.50
(44.92-
56.08)
14.00
(12.42-
19.08)
19.13
(14.31-22.10)
51.00(47.83-
55.25)
Disease  
duration (yr)
3.83
(3.50-4.50)
12.58
(11.40-16.46)
33.42
(24.58-
41.42)
- - -
HbA1c (mmol/
mol)
54
(52-60)
77
(68-90)
63
(53-70) - - -
HbA1c (%) 7.1(6.9-7.6)
9.2
(8.4-10.4)
7.9
(7.0-8.6) - - -
 
Data are expressed as median, interquartile range and proportion. HbA1c in mmol/mol = 10.93 x HbA1c 
(%)-23.5. 
In the P3-patients, the recordings typically yielded a CMAP scan interrupted by 
large gaps shifted toward abnormally high SIs, reflecting motor unit loss, the pres-
ence of enlarged motor unit potentials, and a reduced axonal excitability.
The SI variables S5, S50, and S95 were significantly higher in P1- and P2-patients 
compared with their matched controls (all p values < 0.045) (Figure 2A-C), 
except the S50 for P1-patients vs. C1-controls (p=0.07). In the P3-patients, these 
SI variables were also increased compared with their controls, albeit not signifi-
cantly (Figure 2A-C). The maximum CMAP amplitude was decreased in P2- and 
P3-patients compared with their controls (6.9 (5.9-8.4) mV vs 8.2 (6.8-10.0) 
mV (p 0.11), and 4.3 (1.5-8.2) mV vs 6.1 (5.4-7.5) mV (p 0.09), respectively). The 
CMAP amplitude of the P1-patients did not differ from the CMAP amplitude of 
the C1-controls (5.9 (3.6-8.5) mV vs 6.1 (4.2-8.7) mV (p 0.58)).  
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D50 was significantly decreased in P3-patients compared with their controls (p< 
0.001)(Figure 2D).
Figure 2: Stimulus intensities 
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A: Stimulus intensities (y-axis) required to elicit responses of 5 percent of the maximum CMAP amplitude 
in patients and controls (x-axis).  B: Stimulus intensities (y-axis) required to elicit responses of 50 percent of 
the maximum CMAP amplitude in patients and controls (x-axis).  C: Stimulus intensities (y-axis) required 
to elicit responses of 95 percent of the maximum CMAP amplitude in patients and controls (x-axis).D: D50 
(y-axis) in patients and controls (x-axis). 
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Discussion
Our study demonstrates  increased stimulus intensities (SIs), reflecting reduced 
axonal excitability, in all three groups of patients with T1DM compared with their 
controls. Despite the small group sizes, these reductions in axonal excitability 
were found to be highly significant. This suggests that the CMAP scan is very 
sensitive to the axonal changes that occur with T1DM.  
As a result of our inclusion strategy, we expected a trend toward higher SI values 
from the P1- via the P2- to the P3-group. Indeed, our results show higher SI 
values for the P2-patients than for the P1-patients. We did not expect to find 
aberrant values in the P1-group compared with their controls. The fact that we 
did indicates that reduced axonal excitability (whether stand-alone or as part of 
subclinical DPN) occurs in some individuals in a very early stage of T1DM, despite 
appropriate glycemic control and the absence of other microvascular complica-
tions. We may speculate that these patients are more prone to develop muscular 
atrophy, sensory neuropathy, and/or other microvascular complications. A larger, 
longitudinal study from the diagnosis of T1DM onwards is required to confirm 
that the early impairment of motor nerve excitability observed in this study is 
indeed a sign of subclinical DPN and/or identifies the high risk patients. 
Another intriguing finding was that the SI values in the P3-group are similar to 
those in the P1-group. This may be an effect of a dramatically reduced number of 
remaining, functioning, axons in the P3-group with the most healthy ones surviv-
ing. The number of patients in the P3-group in particular is so small, however, that 
this may equally well be a chance finding that would not recur in a larger study. 
Our findings of impaired axonal excitability are in agreement with a study in 
diabetic mice (11) and with a study in a patient group predominantly consisting of 
patients with type 2 diabetes (24).  Axonal excitability is the result of the interplay 
between sodium and potassium currents in the axolemma, amongst many other 
factors (25). These currents are regulated by the Na+/K+- ATPase pump and 
free-standing sodium and potassium channels (26). Dysfunction of the Na+/K+ 
- ATPase pump is a well-known phenomenon in DPN (11, 18). In addition, several 
studies describe changes in free-standing sodium and potassium channels during 
the process of de- and remyelination (25, 27), a process that may occur both early 
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and late in the disease course of DPN (10, 28). 
In addition to the excitability changes, our study has shown that the maximum 
CMAP amplitude was decreased in the patients with clinical DPN (P3-group) 
and to a lesser extent in the group likely to have subclinical DPN (P2-group). This 
supports the notion that the CMAP amplitude alters relatively late in the disease 
course of DPN (1, 12). As we anticipated this finding, we added D50 as CMAP 
scan measure of axonal loss and reinnervation. D50 was found to be decreased 
in the P3-group but not in the P2- and P1-group. Probably, the normal D50 in the 
P2-group results from the fact that D50 is sensitive only to changes in motor unit 
number in the range between 0 and 100 motor units. Near-normal numbers of 
motor units (200-300) due to mild axonal loss will not result in a decreased D50 
(unpublished data, collected after the current pilot was performed). Hence, D50 
is sensitive to detect the severe axonal damage in clinical DPN but cannot be 
used to assess subclinical DPN.
In designing our study, we used sets of strict inclusion criteria (related to estab-
lished risk factors for DPN) to define different patient groups (1, 6). Hence, we 
hoped to establish that the P1-group would be unaffected and that at least some 
P2-patients would be affected by subclinical DPN. Use of biopsies, a reliable gold 
standard for establishing DPN (8, 29, 30), was not feasible for this pilot study 
format. Consequently, the extent to which conclusions can be drawn regarding 
the diagnostic possibilities of the CMAP scan variables is limited. However, as the 
CMAP scan provides a new type of information on the condition of the motor 
nerve in patients with T1DM, it opens avenues for further research. SI variables, 
reflecting axonal excitability, may be able to detect subclinical DPN in young pa-
tients, whereas a conventional measure such as the maximum CMAP amplitude 
is not. 
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Recently, Professor Malik discussed the lack of an appropriate test for the early 
detection of diabetic neuropathy (DN) (1). He questioned the utility of conven-
tional neurophysiological and symptom-based tests before outlining potential 
small-fiber-focused techniques as measures of subclinical DN (SDN), as il-
lustrated by the elegant techniques of corneal confocal microscopy (1). Since 
improved glycemic control during the early stages of DN may prevent or delay 
nerve function deterioration, timely detection of SDN is important. The rapidly 
increasing prevalence of type 1 diabetes (T1D) in youth, resulting in longer disease 
duration and increased likelihood of developing SDN, underscores this unmet 
need for identifying early markers of SDN. We agree with Professor Malik that 
there are shortcomings in current markers. Indeed, the reliability of sensory nerve 
conduction velocity (NCV) as the ‘gold standard’ to detect SDN in children and 
adolescents with T1D has been questioned (2). 
When we assessed sensory NCV, sensory nerve action potential (SNAP) ampli-
tude of the superficial peroneal and sural nerves, and compound muscle action 
potential (CMAP) scans of the peroneal nerve in young patients with T1D and 
age-matched healthy controls, we found that motor neuron damage may coin-
cide with or even precede sensory damage. While sensory NCV did not differ 
significantly between patients (range 12.5–19.9 years) and controls, nor between 
patients with well-controlled (duration < 5 years, HbA1c < 8.0%) and poorly con-
trolled T1D (duration > 10 years, HbA1c > 8.5% and/or early signs of microvascular 
complications), SNAP amplitudes were lower in patients with poorly controlled 
T1D. Although diagnostic sensitivity was acceptable, accuracy and specificity 
were low (3). Compound muscle action potential (CMAP) scans revealed no 
difference in conventional motor nerve neurophysiological measures (axonal loss 
and re-innervation) between young T1D patients (range 8.08–23.58 years) and 
age-matched healthy controls (4). However, axonal excitability was significantly 
reduced in both well- and poorly controlled young patients and adults with T1D 
when compared with controls. This suggests that whereas early disturbances of 
motor neuronal function cannot be detected using conventional motor nerve 
neurophysiological measures, recently developed axonal excitability measures 
could prove useful in identifying the early signs of nerve function deterioration. 
The abovementioned findings underscore the necessity for ongoing debate on 
appropriate surrogate measures. We caution against a singular focus on sensory 
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nerves as our results indicate that (early) motor nerve dysfunction may also po-
tentially be a suitable marker of SDN. 
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Abstract
Aims
To assess age-specific carotid intima-media thickness (cIMT) in children and 
adolescents with type 1 diabetes and to investigate associations between cIMT, 
age, classical cardiovascular disease (CVD) and other risk factors.
Methods
This study included a cross-sectional analysis of cIMT in 178 patients with type 1 
diabetes and 208 healthy controls across age categories. In patients, the impact 
of gender, socio-economic status, ethnicity, current and historical , body mass in-
dex, blood pressure, haemoglobin A1c  ,high-density lipoprotein and low-density 
lipoprotein cholesterol on cIMT was studied in a retrospective follow-up cohort 
study.
Results
Median cIMT was equally greater in patients versus controls across all age cate-
gories (p ≤ 0.03). Regression models in patients confirmed a lack of association 
between cIMT and classical CVD risk factors.
Conclusions
Children and adolescents with type 1 diabetes showed greater cIMT than controls 
in all age categories. Increased cIMT did not seem to be consistently associated 
with classical adult CVD risk factors, adding to the current debate in pediatrics 
about the impact on classical CVD risk factors to the development of subclinical 
atherosclerosis in type 1 diabetes. Future studies are warranted to determine if 
cIMT could assist in predicting macrovascular complications of type 1 diabetes.
Introduction
Adult patients with type 1 diabetes have a considerably higher risk for cardiovas-
cular disease (CVD) and cardiovascular mortality than healthy adults (1). As an 
increase in carotid intima-media thickness (cIMT) is associated with CVD, cIMT 
is widely used as a surrogate endpoint for subclinical atherosclerosis in adults (2-
4). In addition to classical factors (e.g. hypertension, dyslipidaemia, smoking) (3), 
it is thought that glycaemic control, diabetes duration, and male gender (4, 5), as 
well as factors such as inflammation and genetic predisposition may contribute  
to cIMT increment and CVD risk in adults (6). 
Although longitudinal data are lacking, cIMT is considered to also be a marker 
of subclinical atherosclerosis in children and adolescents with type 1 diabetes. 
However, in this group conflicting results on cIMT were observed when patients 
were compared with healthy controls (7-10). Little is known about age-specific 
differences in cIMT. In a study among children and adolescents with type 1 dia-
betes (aged 8–19 years), cIMT was increased during the first three age quartiles, 
but no further increase was observed in the fourth age quartile (9). Studies on 
the impact of covariables associated with increased cIMT in children and ado-
lescents with type 1 diabetes are contradictory. One study found that cIMT was 
significantly associated with body mass index (BMI) and duration of diabetes (11), 
whereas another study found that age at diabetes onset, insulin dose, and total 
cholesterol level correlated with cIMT (7); systolic blood pressure (SBP) was the 
only factor found to be predictive in both studies (7, 11). In addition, Krantz et al. 
pointed to gender-specific differences in cIMT, with the high-density lipoprotein 
cholesterol (HDL-C)/low-density lipoprotein cholesterol (LDL-C) ratio being 
a significant factor in males, but not females (8) whereas Krebs et al. reported 
that diabetes duration and pulse pressure were significant factors in males; and 
LDL-C, glycated haemoglobin (HbA1c), and duration of diabetes being significant 
in females (12). These contradictory data of the impact of covariables on cIMT in 
children and adolescents with type 1 diabetes may point to a role other than the 
classical CVD risk factors, and also relevant heterogeneity between patients in 
the early stages of the pathophysiological process of subclinical atherosclerosis in 
youngsters. 
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In this study, we aimed to investigate: (a) age-specific differences in cIMT 
between children and adolescents with type 1 diabetes versus healthy controls; 
and (b) associations between cIMT, disease duration, and current and historical 
(past) classical CVD risk factors in children and adolescents with type 1 diabetes. 
We hypothesize that cIMT increases with age and moreover that the difference 
between patients and controls in cIMT will be higher in the older age categories. 
Moreover, we postulate an association between cIMT and historical classical 
CVD risk factors as the development of subclinical atherosclerosis takes several 
years (5).
Methods
Study population
The age-specific cIMT values of 178 children and adolescents with type 1 dia-
betes were compared with those of 208 healthy controls (hereafter referred to 
as ‘controls’) in a cross-sectional study (Figure 1). All eligible patients with type 
1 diabetes aged 9–22 years (inclusive) were recruited between August 2008 
and October 2010 at the outpatient clinic of Diabeter, a large, certified diabetes 
centre in Rotterdam, the Netherlands. Diabeter provides comprehensive and 
advanced management of children and adolescents with type 1 diabetes. Patients 
with inadequately controlled or treated coeliac disease and hypothyroidism, and 
patients treated for growth hormone deficiency or on lipid-lowering medication 
were excluded. 
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Figure 1: Study profile. 
Patients Controls
Did not attend n=20 (9.3%)
Withdrew participation n=5 (2.3%)
Failure in measuring appropriate 
projections n=12 (5.6%)
Included patients n=178
9-10 years
 n=23
11-19 years
n=135
20-22 years
 n=20
Withdrew participation n=20 (8.5%)
Subject had diabetes n=1 (0.4%)
Subject had anorexia n=1 (0.4%)
Failure in measuring appropriate 
projections n=5 (2.1%)
Included students n=208
11-19 years
 n=208
Recruited patients 
n=215
Recruited students 
n=235
The age- and gender-stratified control group included healthy children aged 
11–19 years, and was recruited from a secondary school in Rotterdam in Octo-
ber and November 2011. Information on gender, birth date, ethnic background, 
and concomitant diseases was obtained. Controls with concomitant diseases 
other than attention deficit/hyperactivity disorder were excluded. Study partic-
ipants and parents of minors provided signed informed consent. The study was 
performed in agreement with the Declaration of Helsinki and approved by the 
Medical Ethical Board of the Erasmus Medical Center Rotterdam in Rotterdam, 
the Netherlands. 
Age-specific cIMT data were determined by stratifying the patient and control 
groups into several age categories 11–12, 13–14, 15–16, and 17–19 years for patients 
and controls; and age categories 9–10 and 20–22 years for patients only. The 
impact of anthropometric, HbA1c, and lipid data on cIMT values in the children 
and adolescents with type 1 diabetes was studied using retrospective data from 
this cohort. Longitudinal anthropometric, HbA1c, and lipid data were retrieved 
from electronic patient charts and grouped according to time of measurement. 
Data obtained at a date closest to the date at which cIMT was measured were 
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included in the time frame ‘current’. The time frame during which inclusion of 
‘current’ data was assumed to be reliable was 6 months for anthropometrics, 3 
months for HbA1c, and 12 months for lipids. Past data, obtained between the first 
clinic visit at Diabeter until 12 months before cIMT measurement, were included 
in the time frame ‘historical’. Data on HbA1c and lipids were included if they were 
obtained ≥3 months after diagnosis of type 1 diabetes. For anthropometrics, data 
obtained at a date closest to the first clinic visit (but ≥1 month after diagnosis) 
were included. Diabetes duration at time of cIMT measurement, age at onset of 
type 1 diabetes, gender, and a family history for premature CVD were considered 
independent of the time of measurement. Family history of premature CVD 
(heart attack, coronary bypass surgery, and/or stroke before age 55 years) in first- 
and second-degree relatives was updated at the end of the study period.
Carotid ultrasonography
Common cIMT was measured at the outpatient clinic of the Sint Franciscus 
Gasthuis, Rotterdam, with cIMT in the control group of students was measured 
at their school. All carotid ultrasound scans were performed with an ART-LAB 
411240 arterial analyser (Esaote; Genova, Italy) and carried out by one expe-
rienced sonographer (Noelle van der Meulen; author). Measurements were 
performed according to previously described guidelines (13). Briefly, participants 
lay in a supine position, the head resting comfortably and the neck slightly hyper-
extended and rotated in the opposite direction of the probe. Ultrasound images 
were obtained of the distal 1 cm of the far wall of each common carotid artery 
(CCA) using B-mode ultrasound, resulting in two echogenic lines. These lines 
represent the combined thickness of the intima and media layers of the arterial 
wall. Until September 2, 2009, each CCA was imaged in two different projections: 
CCA right side 120–180° and CCA left side 180–240°. Mean cIMT was calculated 
from these four projections. From September 23, 2009, onwards, each CCA was 
imaged in three different projections (CCA right side 90–120–180°, and CCA left 
side 180–240–270°) and, as a consequence of this protocol change, mean cIMT 
was calculated as the mean of six projections. If information on one projection or 
one projection of each CCA was missing, mean cIMT was calculated as the mean 
of the four or five remaining projections. 
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Anthropometric data
BMI data were converted to standard deviation scores (SDS) and SBP to percen-
tiles on the basis of commonly applied reference values (14-17). A high BMI was 
defined as a BMI ≥ +2 SDS. A normal BMI was defined as a BMI < +2 SDS.
Laboratory data
HbA1c was measured at every clinic visit by an immunochemical assay (Vantage 
System; Siemens Medical Solutions Diagnostics, Tarrytown, NY, USA) with intra- 
and inter-assay coefficient of variation (CV) values of < 3.7% and < 4.3%, respec-
tively. 
LDL-C, HDL-C, and total cholesterol (TC) were assessed in non-fasting state 
at a frequency recommended by the International Society for Pediatric and 
Adolescent Diabetes guidelines (18). LDL-C, HDL-C, and TC were measured by 
enzymatic colorimetric assay on a Hitachi Cobas C501 analyser (Roche Diagnos-
tics; Mannheim, Germany) with an intra- and inter-assay CV deemed accept-
able according to the External Quality Assurance Services in the Netherlands: 
intra-assay CV: LDL-C 0.90%, HDL-C 0.70%, and TC 1.10%; and inter-assay CV: 
LDL-C 1.90%, HDL-C 0.90%, and TC 1.60%. Until 2006 LDL-C was calculated 
using the Friedewald formula; from 2006 onwards, a direct measurement for 
LDL-C was used. For the historical data, intra-individual median LDL-C, HDL-C, 
TC, and HbA1c were used, and the CV of HbA1c (ratio of intrapersonal HbA1c 
standard deviation [SD]/mean HbA1c) was utilized as a measure of historical 
HbA1c variability (19). 
Statistical analysis
Categorical variables were expressed as proportions and percentages. Continu-
ous variables were expressed as mean ± SD for normally distributed variables, or 
median with interquartile range (IQR) for skewed data. Differences were tested 
by –2 test or Fisher’s Exact test in the case of categorical variables, and indepen-
dent Student t-test or Mann-Whitney U test in the case of continuous variables. 
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Table 1: Demographic, anthropometric, and laboratory data of the patients, stratified by age
Patients aged < 15.3 years
(n = 89)
Patients aged ≥ 15.3 years
(n = 89)
Age, median (IQR), years 12.5 (10.9–14.2) 18.6 (17.3–20.0)
Diabetes duration, median (IQR), years 5.6 (3.6–8.3) 10.0 (6.3–14.0)
Female, n (%) 37 (42) 44 (49)
Family history premature CVD, n (%)
   Positive
   Negative
   Unknown 
23 (26)
60 (67)
6 (7)
17 (19)
63 (71)
9 (10)
BMI-current, n (%)
   BMI ≤ −2 SDS
   BMI > −2 SDS and < 0 SDS
   BMI ≥ 0 SDS and BMI < +2 SDS
   BMI ≥ +2 SDS
1 (1)
11 (12)
67 (75)
10 (11)
–
13 (15)
65 (73)
9 (10)
BMI-historical, n (%)
   BMI ≤ −2 SDS
   BMI > −2 SDS and < 0 SDS
   BMI ≥ 0 SDS and BMI < +2 SDS
   BMI ≥ +2 SDS
-
20 (23)
59 (66)
7 (8)
-
15 (17)
67 (75)
3 (3)
SBP-current percentile, median (IQR) 79.0 (56.5–91.0) 88.0 (68.0–98.0)
SBP-historical percentile, median (IQR) 73.0 (56.5–92.3) 87.0 (68.0–94.0)
HbA1c-current 
   Median (IQR), mmol/mol
   Median (IQR), %
64 (57–72)
8.0 (7.4–8.7)
68 (58–77)
8.4 (7.5–9.2)
HbA1c-historical, 
   Median (IQR), mmol/mol
   Median (IQR), %
61 (57–65)
7.7 (7.4–8.1)
66 (58–73)
8.2 (7.5–8.8)
HbA1c CV-historical, median (IQR) 0.070 (0.051–0.088) 0.073 (0.058–0.095)
LDL-C-current, median (IQR), mmol/l 2.3 (2.1–2.7) 2.6 (2.1–3.0)
LDL-C-historical, median (IQR), mmol/l 2.2 (1.8–2.5) 2.5 (2.0–2.8)
HDL-C-current, median (IQR), mmol/l 1.6 (1.4–1.8) 1.4 (1.2–1.7)
HDL-C-historical, median (IQR), mmol/l 1.5 (1.2–1.7) 1.4 (1.1–1.6)
cIMT, median (IQR), mm 0.423 (0.390–0.446) 0.413 (0.386–0.449)
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Missing values (patients aged < 15.3 years/ patients aged ≥ 15.3 years): BMI-current (0/2); BMI-historical 
(3/4); SBP-current (0/1); SBP-historical (3/4); HbA1c-current (0/2); HbA1c-historical (5/3); HbA1c CV-his-
torical (7/6); LDL-C-current (13/13); LDL-C-historical (27/16); HDL-C-current (15/10); HDL-C-historical 
(25/18). BMI, body mass index; cIMT, carotid intima-media thickness; CV, coefficient of variation; CVD, 
cardiovascular disease; HbA1c, glycated haemoglobin; HDL-C, high-density lipoprotein cholesterol; IQR, 
interquartile range; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; SDS, standard 
deviation score.
We found that diabetes duration and age at onset were confounding factors 
(multicollinearity). Diabetes duration was included as an independent variable, 
using age as a stratifying variable, and excluded age at onset for further statistical 
analysis. Weight for height SDS, diastolic blood pressure, and TC were not  
analysed further because these variables were highly correlated with BMI, SBP, 
and LDL-C, respectively.
Median cIMT values and differences in cIMT between patients with type 1 diabe-
tes and controls were analysed across several age categories (11–12, 13–14, 15–16, 
and 17–19 years). The age categories 9–10 years and 20–22 years were included 
for patients only, as there were no controls available in these age ranges. 
For the patient group, two multiple-regression analyses were performed to iden-
tify any associations between cIMT and duration of type 1 diabetes, socio-eco-
nomic status (SES), gender, ethnicity (Western/non-Western) and various 
classical CVD risk factors. Model 1 included an ‘enter’ analysis (in which we 
specified the set of variables that make up the model) whereas model 2 included 
a backward stepwise regression analysis. To adjust for confounding, we stratified 
patients by median age: patients aged < 15.3 years and patients aged ≥ 15.3 years. 
Median age was chosen to ensure equal group sizes. 
The significance level was set at p < 0.05 (two-sided). All analyses were per-
formed with IBM SPSS Statistics 20.0 for Windows (SPSS Inc.; Chicago, IL, USA).
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Results
Characteristics of patients with type 1 diabetes and controls
Patients with type 1 diabetes (n = 135 patients age-matched to n = 208 controls 
for age categories available for both patients and controls: 11–12, 13–14, 15–16, and 
17–19 years) were older than controls (patients: median age 15.3 [IQR 13.4–18.2] 
years; controls: median age 14.6 [IQR 13.4–15.7] years; p = 0.001). The proportion 
of females was lower in the patient group compared with the control group (45% 
vs. 63%; p = 0.001). The ethnic distribution was different for patients when com-
pared with controls: 73% of patients originated from Western Europe, 16% were of 
Mediterranean origin, and 11% had another non-Western European background. 
For the control group these proportions were 79%, 4%, and 17%, respectively 
(Fisher’s Exact test; p = 0.001). Table 1 presents the demographic, anthropomet-
ric, and laboratory data of patients with type 1 diabetes after stratification by 
age < 15.3 or ≥ 15.3 years. The supplemental table presents the same data for the 
stratification in the various age categories.
Age-specific cIMT in patients with type 1 diabetes and controls
The overall cIMT was significantly greater in patients with type 1 diabetes when 
compared with controls (mean ± SD: 0.420 ± 0.047 mm vs. 0.390 ± 0.033 mm; P  
< 0.001). The same applied to the separate age categories (Figure 2).There were 
no gender differences in cIMT within age categories (see Table 2B). 
Association of cIMT with classical CVD risk factors in patients with type 1 diabetes 
Maximum follow-up time was 15.4 years for the laboratory data, with a median 
follow-up of 3.1 years. No associations were found between cIMT and HbA1c and 
LDL-C (Figure 3). Results of the regression analyses are presented in Tables 2A 
(enter analysis) and 2B (backward analysis). While some variables in these anal-
yses were significant, beta values were generally low and the predictive power of 
these variables was low. These variables did not contribute substantially to cIMT.
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Table 2A: Regression analyses: Model 1 (enter analysis).
Patients < 15.3 years old
(‘Younger’ group)
Adjusted R2: 0.130 (P = 0.19)
Patients ≥ 15.3 years old
(’Older’ group)
Adjusted R2: 0.105 (P = 0.18)
B 95%CI P value B 95% CI
P 
value
Duration of type 1 diabetes 
(years) 0.003
-0.003  / 
0.009 0.27 0.006 0.002 / 0.010 0.01
Gender (female vs male) -0.003 -0.033 / 0.027 0.85 0.005 -0.028 /0.029 0.74
Ethnicity (Non-Western vs 
Western) -0.003 -0.035 / 0.030 .86 -0.005 -0.046 /0.036 0.82
Socio-economic status -0.005 -0.018 / 0.009 0.48 0.007 -0.007 / 0.021 0.33
Family history unknown vs 
negative/positive -0.004 -0.056 / 0.048 0.88 -0.043 -0.107 / 0.022 0.19
BMI high vs normal-current 0.032 -0.010 / 0.075 0.13 0.008 -0.05 / 0.067 0.77
BMI high vs normal-historical -0.009 -0.064 / 0.046 0.74 -0.038 -0.148 / 0.072 0.49
SBP-current 0.00 -0.001 / 0.001 0.96 0.00 0.00 / 0.001 0.24
SBP-historical 0.00 0.00 / 0.001 0.12 0.00 -0.001 / 0.001 0.78
LDL-C-current 0.010 -0.026 / 0.046 0.58 -0.010 -0.038 / 0.018 0.49
LDL-C-historical 0.016 -0.028 / 0.060 0.47 0.024 -0.007 /0.054 0.13
HDL-C current -0.019 -0.080 / 0.041 0.52 -0.002 -0.068 /0.063 0.94
HDL-C historical 0.005 -0,052 / 0.062 0.86 0.002 -0.055 /0.059 0.94
HbA1c-current -0.005 -0.018 / 0.008 0.44 0.002 -0.011 / 0.016 0.76
HbA1c-historical 0.008 -0.013  /0.028 0.46 -0.022 -0.044 / 0.00 0.052
HbA1c CV-historical -0.167 -0.493 / 0.160 0.31 0.347 -0.095 / 0.788 0.12
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Table 2B: Regression analyses: Model 2 (backward stepwise analysis). 
 
Patients < 15.3 years old
(‘Younger’ group)
Adjusted R2: 0.246, (P = 0.002)
Patients ≥ 15.3 years old
(’Older’ group)
Adjusted R2: 0.202, (P = 0.003)
B 95%CI P value B 95% CI
P 
value
Duration of type 1 diabetes (y) 0.005 0.001 / 0.009 0.02 0.006 0.002 / 0.009 0.001
BMI high vs normal-current 0.037 0.008 / 0.066 0.014 na na na
LDL-C-historical 0.024 0.002 / 0.046 0.031 na na na
SBP na na na 0.000 0.00 / 0.001 0.063
HbA1c - historical na na na -0.021 -0.037 / -0.05 0.010
HbA1c CV - historical na na na 0.373 0.031 / 0.715 0.033
‘NA’: was not included in the backward stepwise analysis CVD, cardiovascular disease; LDL-C, LDL choles-
terol; HDL-C, HDL cholesterol; SBP, systolic blood pressure; HbA1c CV, HbA1c coefficient of variation 
BMI-high: BMI ≥ + 2 SDS; BMI-normal: BMI < +2 SDS.
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Figure 2: Age-specific median cIMT of children and adolescents with type 1 diabetes and controls.
0.60
0.55
0.50
0.45
0.40
0.35
0.30
0.25
cI
M
T(
m
m
)
9-10 11-12 13-14 15-16 17-19 20-22
Age category (year)
n = 23 n = 30 n = 36 n = 28 n = 93 n = 28 n = 63 n = 49 n = 16 n = 20
0.409 0.416
0.437
0.423
0.410
0.415
0.392 0.389 0.393
0.393
P = 0.014 P < 0.001 P = 0.030 P = 0.002
Patients Controls
The mean cIMT for each patient was calculated from 4 projections in 103 patients and 1 control, from 5 pro-
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are outliers.  cIMT, carotid intima-media thickness. 
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Figure 3: Association of cIMT with HbA1c (A) and LDL-C (B). 
A
 
B
 
 
 
cIMT, carotid intima-media thickness; HbA1c, glycated haemoglobin; LDL-C, low-density lipoprotein 
cholesterol.
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Discussion
Mean cIMT of the entire patient group was greater than in the control group. 
These results are consistent with some previous studies (7, 8, 10), but not with 
other studies (9, 20). In our age-specific analysis of cIMT, we found that median 
cIMT was significantly and equally greater in children and adolescents with type 1 
diabetes when compared with controls across all age categories. Our analysis on 
factors contributing to increased cIMT in patients showed only limited contribu-
tion of classical adult CVD risk factors, glycaemic variability, and a positive family 
history for premature CVD; despite some significant results, effect sizes were 
small and predictive power was low.
The lack of a clear contribution of classical CVD risk factors to cIMT in our study 
and in previously published pediatric studies (7, 8, 11, 12) may be explained by 
differences in age, diabetes duration, length of follow-up, and CVD risk cate-
gorisation (current vs. historical data). Alternatively, the interplay between adult 
classical CVD risk factors may change over time and/or may contribute in a more 
complex way to the vascular changes and cIMT increase seen in type 1 diabetes. 
This may be the case in children and adolescents in particular, but also in adults 
with type 1 diabetes as outlined in the recently published American Heart As-
sociation and American Diabetes Association scientific statement (4), in which 
doubts are raised on the relative contributions of classical CVD risk factors to 
CVD in adults with type 1 diabetes (6). We postulate that multiple factors such 
as: immune and inflammatory status (21, 22); varying glycation due to, as yet 
unravelled, genetic factors (23); epigenetic factors (24); increased glucose vari-
ability, specifically in children and adolescents (25, 26); glycaemic variability (19); 
and possible age-related factors, such as different timing of pathophysiological 
events — several vascular changes only occur during puberty (27) — are involved 
in increases of cIMT in type 1 diabetes. Prospective longitudinal studies including 
(at least) more sequential measurements of cIMT, Tanner stages, (early signs of) 
microvascular complications, classical CVD risk factors, glycaemic variability, and 
markers of immune status and inflammation are needed to better assess patient 
heterogeneity and identify factors contributing to vascular changes.
An important strength of this study is that we compared the median cIMT of pa-
tients and controls in different age categories, showing that the median cIMT of 
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patients is consistently higher than in controls for all age categories. In addition, 
we showed that cIMT does not appear to increase with age. However, it should 
be noted that the relationship with age was studied cross-sectionally instead of 
longitudinally: previous studies, that were cross-sectional as well, were also not 
consistent with respect to the effect of age on cIMT. Dalla Pozza et al (7) found 
an association between age and cIMT in young patients with type 1 diabetes, 
whereas Margeirsdottir et al only found this for the first three age quartiles in 
young patients with type 1 diabetes (9). Jourdan et al (28) found only a slight 
increase of cIMT with age in controls. Our data indicated that significant het-
erogeneity exists between patients and that a subset of the children and young 
adolescents with type 1 diabetes may be prone to developing CVD at a very 
young age. These findings are worrisome, and underscore the need for further 
research into (modifiable) factors that affect cIMT.  Another strength of this 
study is that both current and historical data of CVD risk factors were available 
for regression analyses, as were SES, ethnicity and an updated family history for 
premature CVD. The latter did not affect cIMT, which is consistent with results 
from previous studies in patients with type 1 diabetes (8, 9). However, this is in 
contrast with studies in healthy volunteers in which ‘positive family history for 
premature CVD’ affects cIMT (29, 30). This may be explained by the inclusion of 
older adolescents in one of these studies (30), correlating with older parents and 
subsequently a higher likelihood of CVD events, and also with a positive family 
history in the other study (29). 
A limitation of the study could be that, despite a maximum follow-up window of 
15.4 years for the laboratory data, the median follow-up of only 3.1 years may be 
too short to detect the detrimental effects of CVD risk factors on cIMT. Also we 
did not include patient smoking status in the analysis due to low prevalence, pos-
sibly as a result of underreporting and life style education. Furthermore, we did 
not investigate if CVD risk factors, SES, smoking, and other lifestyle factors were 
different in the control group, complicating the interpretation of the age-specific 
comparison of cIMT between patients and controls. Indeed, several assumed 
CVD risk factors may be more unfavourable in children and adolescents with 
type 1 diabetes than in controls (7, 9, 10). However, reported differences in these 
risk factors between patients and controls are small (9, 10). In addition, as already 
mentioned, the contribution of CVD risk factors to cIMT is controversial (6, 7, 9, 
10, 12). Therefore, we feel that the lack of data on CVD risk factors of controls has 
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not affected our conclusion that the age-specific cIMT is greater in patients with 
type 1 diabetes when compared with controls. Another point to note is that pro-
spective repeated measurements of cIMT in the same patient group would have 
strengthened the results. Although the switch in measurement protocol (number 
of projections) did not significantly influence the mean cIMT measurements 
(median difference 0.003 mm), future studies should have consistent method-
ology throughout the study. Finally, data on intra-rater cIMT measurement error 
was unavailable. In our study, the mean difference in cIMT between the study 
and control groups was mean 0.030 mm (varying between 0.023–0.048 mm for 
the separate age groups), which is comparable to the results found by others: 
approximately 0.010–0.04 mm (7-10). We assume that the published coefficients 
of variation (7, 8, 10) also apply to our study, this would imply that differences 
in mean cIMT of approximately 0.022 mm or smaller are differences potentially 
attributable to intra-rater measurement error.
Conclusions
In summary, this study shows that cIMT, a surrogate marker for subclinical ath-
erosclerosis, is greater in children and adolescents with type 1 diabetes than in 
controls across all age categories. Increases in cIMT seem independent of both 
current and historical classical CVD risk factors and, therefore, the increases in 
cIMT seem to be driven, at least in part, by a different pathophysiological pro-
cess in children and adolescents with type 1 diabetes when compared with adult 
patients. To help identify those patients who are at-risk of macrovascular com-
plications, larger studies with repeated measurements of cIMT in children and 
adolescents with type 1 diabetes, including classical adult CVD risk factors and 
other potentially contributing factors such as immune status and genetic predis-
position, are warranted. 
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Supplemental table: Demographic, anthropometric, and laboratory data in the patients, stratified for age
Age category (years) 9–10(n = 23)
11–12
(n = 30)
13–14
(n = 28)
15–16
(n = 28)
17–19
(n = 49)
20–22
(n = 20)
Diabetes duration in years, median (IQR) 5.5 (3.5–6.8) 6.4 (4.6–8.6) 6.1 (3.5–9.3) 6.2 (3.2–11.4) 9.9 (6.4–14.1) 12.4 (9.1–14.5)
Gender: Female, n (%) 9 (39) 13 (43) 12 (43) 10 (36) 26 (53) 11 (55)
Family history premature CVD, n (%)
   Positive
   Negative
   Unknown
6
16
3
9
20
1
6
20
2
7
17
4
11
34
4
1
16
3
BMI current: 
   BMI ≤ -2 SDS
   BMI > -2 SDs and < 0 SDS
   BMI ≥0 SDs and BMI < +2 SDS
   BMI ≥ +2 SDs
-
3
18
2
-
7
21
2
-
-
23
5
1
4
20
3
-
6
36
6
n = 1 missing
-
4
14
1
n = 1 missing
BMI historical:
   BMI ≤ -2 SDS
   BMI > -2 SDS and < 0 SDS
   BMI ≥ 0 SDS and BMI < +2 SDS
   BMI ≥ +2 SDS
-
5
13
4
n = 1 missing
-
9
20
-
n = 1 missing
-
4
21
2 
n = 1 missing
-
6
17
2
n = 1 missing
-
8
38
2
n = 1 missing
-
3
17
-
SBP-current percentile, median (IQR) 64 (36–93) 69 (57–84) 84 (66–92) 89 (70–99) 88 (62–96)n = 1 missing 88 (72–99)
SBP-historical percentile, median (IQR) 78 (61–91)n = 1 missing
73 (45–91)
n = 1 missing
73 (57–95)
n = 1 missing
84 (56–94)
n = 1 missing
88 (68–95)
n = 1 missing
84 (69–88)
DBP current 50 (32–63) 30 (16–46) 33 (20–66) 53 (22–84) 47 (30–72)n = 1 missing 59 (44–82)
DBP historical 65 (30–81)n = 1 missing
36 (20–59)
n = 1 missing
64 (42–82)
n = 1 missing
51 (26–74)
n = 3 missing
61 (47–80)
n = 1 missing 62 (46–75)
HbA1c-current, 
   Median, mmol/mol (IQR)
   Median, % (IQR)
61 (57–66)
7.7 (7.4–8.2)
64 (55–70)
8.0 (7.2–8.6)
65 (61–74)
8.1 (7.7–8.9)
67 (58–86)
8.3 (7.5–10)
70 (61–84)
8.6 (7.7–9.8)
n = 2 missing
64 (56–73)
8.0 (7.3–8.8)
HbA1c-historical, 
   Median, mmol/mol (IQR)
   Median, % (IQR)
60 (55–63)
7.6 (7.2–7.9)
n = 1 missing
62 (55–66)
7.8 (7.2–8.2)
n = 2 missing
62 (57–66)
7.8 (7.4–8.2)
n = 2 missing
65 (57–77)
8.1 (7.4–9.2)
n = 2 missing
67 (60–73)
8.3 (7.6–8.8)
n = 1 missing
66 (63–74)
8.2 (7.9–8.9)
LDL-C-current, median mmol/l (IQR) 2.4 (2.1–2.7)n = 4 missing
2.3 (2.1–2.6)
n = 4 missing
2.4 (2–2.7)
n = 3 missing
2.5 (2.1–2.9)
n = 7 missing
2.7 (2.1–3.1)
n = 5 missing
2.6 (2.0–2.9)
n = 3 missing
LDL-C-historical, median mmol/l (IQR) 2.2 (1.9–2.5)n = 6 missing
2.1 (1.8–2.5)
n = 6 missing
2.5 (1.8–2.8)
n = 10 missing
2.4 (1.9–2.6)
n = 11 missing
2.5 (2.2–2.9)
n = 9 missing
2.3 (2.0–2.9)
n = 1 missing
HDL-C-current, median mmol/l (IQR) 1.7 (1.3–1.8)n = 5 missing
1.7 (1.5–2)
n = 5 missing
1.5 (1.4–1.7)
n = 3 missing
1.5 (1.3–1.6)
n = 5 missing
1.3 (1.2–1.6)
n = 5 missing
1.6 (1.3–1.8)
n = 2 missing
HDL-C-historical, median mmol/l (IQR) 1.4 (1.2–1.6)n = 5 missing
1.5 (1.4–1.9)
n = 6 missing
1.5 (1.2–1.8)
n = 10 missing
1.4 (1.2–1.7)
n = 10 missing
1.4 (1.1–1.6)
n = 11 missing
1.3 (1.1–1.8)
n = 1 missing
HbA1c CV-historical, median (IQR)
0.070 
(0.06–0.08)
n = 1 missing
0.07 
(0.05–0.09)
n = 2 missing
0.08 
(0.05–0.10)
n = 3 missing
0.06 
(0.05–0.09)
n = 4 missing
0.08 
(0.06–0.10)
n = 3 missing
0.06 
(0.05–0.08)
cIMT, median mm (IQR) 0.409 (0.385-0.430)
0.416 
(0.398-0.446)
0.437
(0.404-0.466)
0.423 
(0.366-0.447)
0.410 
(0.384-0.452)
0.415 
(0.395-0.445)
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Abstract
Background
Early identification of children and adolescents with type 1 diabetes at high risk 
for development of complications is important, as early intervention may pre-
vent further deterioration. Here we investigate the applicability of assessing skin 
advanced glycation end products (sAGEs) by skin autofluorescence (SAF) as a 
potential surrogate risk marker.
Methods
This study included a cross-sectional analysis of SAF in 77 patients with type 1 di-
abetes mellitus and 118 healthy controls across age categories (11–12, 13–14, 15–16, 
and 17–19 years old). In patients, the impact of current and historical glycated 
hemoglobin (HbA1c) values, age, and duration of diabetes on SAF was studied in 
a retrospective cohort study and analyzed with multivariable analyses.
Results
SAF was significantly and similarly higher in patients when compared with con-
trols across all age categories (P ≤ 0.009). For patients, age, duration of diabetes, 
and current and historical HbA1c were associated with SAF in univariate analysis. 
Multivariate analysis showed no association between HbA1c and SAF. A sub-
group of patients with a HbA1c-within-target (≤ 7.5%/59 mmol/mol) were ob-
served to have high SAF. 
Conclusion
Children and adolescents with type 1 diabetes show higher SAF than controls. 
The presumed correlation of high HbA1c with high SAF does not exist in all pa-
tients. Thus, use of this non-invasive measure may provide a surrogate marker for 
diabetic complications, additional to HbA1c. 
Introduction
Reactive oxygen species and non-enzymatic reactions between sugars and 
amino groups of proteins (‘Maillard reaction’) are involved in the formation of 
advanced glycation end products (AGEs) (1). AGEs cause oxidative stress-related 
tissue damage (1), which plays an important role in microvascular and macrovas-
cular complications in diabetes (2). 
As skin collagen has a half-life of 10–15 years (3), skin AGEs (sAGEs) represent 
long-term glycemia. Accumulation of sAGEs can be assessed easily and non-in-
vasively by measuring skin autofluorescence (SAF) (4). sAGEs have been pro-
posed as a surrogate measure for risk assessment additional to HbA1c in patients 
with diabetes (5). In adults, increased levels of sAGEs were found in patients 
who developed complications (5–7). As early intervention may prevent damage 
later in the disease course of diabetes (8), identification of young patients at high 
risk for micro- and macrovascular complications is of paramount importance 
(9). SAF may be an effective measurement to identify this disadvantaged group. 
Previous studies assessed SAF in a rather heterogeneous group of children and 
adolescents with type 1 diabetes (10, 11), but some lacked a proper control group 
(12, 13). Felipe et al. (14) found SAF to be weakly associated with mean HbA1c of 
the preceding period and with diabetes duration.  
Here we investigate if SAF reflects glycemic control expressed by HbA1c in a 
homogeneous study population. SAF in Dutch Caucasian children and adoles-
cents with type 1 diabetes was compared with SAF in healthy Caucasian controls. 
In patients, associations of SAF with age, diabetes duration, gender, and current 
and historical (past) HbA1c as a reflection of long-term glycemic control were 
determined. We hypothesize that SAF will be higher in patients compared with 
controls and that it will associate with the variables age, historical HbA1c, and 
diabetes duration.
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Methods
Study design and population
The study design was a retrospective cohort study of patients with type 1 di-
abetes and healthy controls. Patients aged 11–19 years with type 1 diabetes ≥ 3 
months were recruited between April 2010 and January 2013 while visiting the 
outpatient clinic of Diabeter, a certified center of reference for diabetes care in 
Rotterdam, Netherlands. Diabeter provides comprehensive and advanced man-
agement for children and adolescents with type 1 diabetes. Patients were only 
included if they were Caucasian and if measurements of SAF and HbA1c were 
performed on the same day. Patients with inadequately controlled celiac disease, 
hypothyroidism, and those using lipid-lowering therapy were excluded. 
The healthy control group was recruited from a secondary school in Rotterdam in 
October and November 2011. Controls with missing data, non-Caucasian ethnic-
ity, and concomitant diseases other than attention deficit/hyperactivity disor-
der were excluded. Study participants and parents of minors provided signed 
informed consent. The study was approved by the Medical Ethical Board of the 
Erasmus Medical Center, Rotterdam, Netherlands, and performed in accordance 
with the Declaration of Helsinki. 
Anthropometric and laboratory data 
In controls, information on gender, ethnic background, and concomitant dis-
eases was collected. Anthropometric and laboratory data were not obtained for 
this group. In patients, information on duration of diabetes, gender, body mass 
index (BMI), blood pressure, current HbA1c, and HbA1c values in the past (called 
‘historical HbA1c’ from here on) was retrieved from electronic patient charts. 
Information on BMI and blood pressure was included if measurements were 
performed within a time interval of 1 month around the SAF measurement. BMI 
was converted to standard deviation scores (SDS): a high BMI was defined as 
a BMI ≥ +2 SDS. A normal BMI was defined as a BMI < +2 SDS (15–17). Systolic 
blood pressure (SBP) and diastolic blood pressure (DBP) were converted to 
percentiles (18). HbA1c was measured at every clinic visit by immunochemical 
assay (Vantage System, Siemens Medical Solutions Diagnostics, Tarrytown, NY) 
with intra- and inter-assay coefficients of variation of < 3.7% and < 4.3%, respec-
tively. Current HbA1c was defined as the HbA1c measured on the same day as 
109
Advanced glycation end products (AGEs) in skin
SAF. Historical HbA1c was defined as the median intrapersonal HbA1c value of 
multiple HbA1c data included from the first clinic visit onwards. Historical HbA1c 
was only determined if the first HbA1c measurement was done ≥ 3 months after 
the diagnosis of type 1 diabetes and if ≥ 3 HbA1c measurements were done in the 
period from the first measurement to the current HbA1c measurement (current 
HbA1c measurement not included). A current or historical HbA1c > 7.5%/59 
mmol/mol was defined as ‘HbA1c-above-target' HbA1c whereas an HbA1c of ≤ 
7.5%/59 mmol/mol was defined as (relatively) ‘Hba1c-within-target’ HbA1c (19).
SAF measurements
Patient SAF measurements were performed at Diabeter. Measurements of con-
trols were performed at their school. The volar side of the forearm was measured 
with the AGE Reader CU autofluorescence reader (Diagnoptics BV, Groningen, 
Netherlands), making sure that the site of measurement was clean. The auto-
fluorescence reader illuminates a skin surface of approximately 1 cm2 with an 
excitation light source between 300 and 420 nm (peak excitation ∼350 nm) (20). 
Three independent measurements were performed in approximately 30 seconds: 
the arm was repositioned between measurements. The mean of the three meas-
urements was displayed by the SAF reader in arbitrary units. Previously, Sugisawa 
et al. (21) reported a coefficient of diurnal variation of 3.7% and a coefficient of 
daily variance of 4.6%.
Statistical methods
Due to the lack of prior data on SAF measurements in patients and controls 
as well as absence of data on the relationship between HbA1c and SAF in DM 
patients, formal sample size could not be calculated at study onset. Instead, our 
aim was to include at least 100 students and at least 70 diabetics during the study 
period.
Normal distributions were expressed as mean with SD. Continuous variables with 
skewed distributions were expressed as median with interquartile range (IQR). Cat-
egorical variables were expressed as proportions and percentages. Differences in 
continuous variables between groups were tested with the Mann-Whitney U test. 
Differences in categorical variables between groups were tested by the chi-squared 
test or Fisher’s exact test. Correlations were tested with Pearson’s rho in case of 
normal distribution and Spearman’s rho in case of skewed distribution.  
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Patients with type 1 diabetes and controls were stratified into multiple age cate-
gories (11–12, 13–14, 15–16, and 17–19 years). For each age category, patients were 
stratified according to HbA1c-above-target and HbA1c-within-target. For both 
patients with HbA1c-above-target and HbA1c-within-target, SAF was descrip-
tively compared with SAF of controls.
Univariate and multiple linear regression analyses were performed. Univariate 
linear regression analyses were used to assess the impact of the following covari-
ables on SAF: age; diabetes duration (≤ 4 years, 4 to <10 years, and ≥ 10 years); 
gender; current HbA1c (current value, and HbA1c-above-target/HbA1c-with-
in-target); and historical HbA1c (historical value, and HbA1c-above-target/
HbA1c-within-target). BMI was not included due to low variability in BMI values. 
SBP and DBP were not included because no associations with SAF were found. 
Multiple linear regression analyses were performed using two models. Model 1 
assessed the impact of age and diabetes duration on SAF. In model 2, current 
and historical HbA1c were added to the model. A P value < 0.05 was considered 
statistically significant.
Results
Study population
A total of 99 patients with type 1 diabetes and 141 controls were recruited, of 
whom 77 patients and 118 healthy controls were included (Figure 1). Baseline 
characteristics of patients and controls are presented in table 1. The median age 
of patients with type 1 diabetes was higher than controls (P = 0.004). Females 
were significantly overrepresented in the control group (P = 0.042). Historical 
HbA1c was determined in 73 patients (median 26 HbA1c measurements; IQR 
17–37; range 3–71) in a period of 4.12 years (IQR 2.43–6.07 years; range 0.75–13.88 
years). 
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Figure 1: Study profile. 
Patients Controls
Concomitant diseases n=11 (11.1%)
Non-caucasian n=9 (9.1%)
No HbA1c available on date of 
SAF measurement n=2 (2.0%)
Included patients n=77
Concomitant diseases n=2 (0.9%)
Non-caucasian/unknown n=21 (9.8%)
Included students n=118
Recruited patients 
n=99
Recruited students 
n=141
SAF, skin autofluorescence.   
 
SAF measurements in controls and patients
Figure 2 shows SAF measurements per age category for the controls, and for the 
patients with historical HbA1c-above-target and HbA1c-within-target. Both the 
overall SAF (patients: median SAF 1.40 [1.23-1.54]; controls: mean SAF 1.14 [0.14], P 
< 0.001) and the median SAF in the different age categories were significantly higher 
in patients when compared with controls (Figure 2). In the control group, median 
SAF  increased from 1.10 [IQR 1.00–1.20] in the age category 11-12 years to 1.40 [IQR 
1.10-1.40] in the age category 17–19 years. In the patient group, the same pattern was 
seen: in the age category 11–12 years, median SAF was 1.24 [IQR 1.19-1.40], and in the 
age category 17–19 years, median SAF was 1.53 [IQR 1.48-1.66] (Figure 2). 
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Table 1: Baseline characteristics of patients with type 1 diabetes and healthy controls
Patients: n=77 Controls: n=118
Age, years 15.3 (13.6–17.0) 14.4 (13.1–15.4)
Gender: female, n (%) 39 (50.6%) 77 (65.3)
Diabetes duration, years (IQR) 6.6 (3.5-9.5) NA
Age at diabetes onset, years (IQR) 8.9 (5.7–11.4) NA
SBP (percentile) 78 (49–91)a NA
DBP (percentile 37 (21–66)a
BMI, n (%)
   ≤ -2 SDS
   > -2 SDS and < 0 SDS
   ≥ 0 SDS and < +2 SDS
   ≥ +2 SDS
-
16 (21.6)b
55 (74.3)b
3 (4.1)b
NA
HbA1c Current 8.46 (1.35) NA
Median Intrapersonal Historical HbA1c, % (IQR) 8.0 (7.48–8.60)c NA
 
a n = 69, b n = 74, c n = 73; DBP, diastolic blood pressure; IQR, interquartile range; SBP, systolic blood pres-
sure; SDS, standard deviations score.
Impact of HbA1c on SAF in patients
Within the patient group, median SAF of patients with a current HbA1c-with-
in-target (n=13) was 1.32 [IQR 1.19-1.52] and of patients with a historical HbA1c-
above-target (n=64) 1.40 [IQR 1.22-1.54](P = 0.654). In the same group, median 
SAF of patients with a historical HbA1c-within-target (n=19) was 1.36 [IQR 1.23-
1.50] and of patients with a historical HbA1c-above-target (n=54) 1.41 [1.23-1.54]
(P = 0.580). There were also no statistically significant differences in SAF be-
tween the HbA1c-above-target and HbA1c-within-target patients for the various 
age categories (Figure 2). 
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Figure 2: Age-specific median skin autofluorescence (SAF) in patients with a HbA1c-above-target (> 
7.5%/59 mmol/mol) and a HbA1c-within-target (≤ 7.5%/59 mmol/mol), compared with controls. P-values: 
comparison of patients vs controls per age category by Mann-Whitney U test. Error bars: interquartile 
range.
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Figure 3 shows the association between historical HbA1c and SAF. The Spearman 
correlation coefficient between historical HbA1c and SAF was 0.292 (P = 0.012). 
Figure 3 also shows that 11 patients with a historical HbA1c-within-target had 
an elevated SAF > 1.28 (mean SAF of controls + 1 SD), whereas 1 patient with a 
historical HbA1c-above-target had a decreased SAF < 1.00 (mean SAF of controls 
-1 SD). 
Univariate linear regression analyses (Table 2) showed a significant impact of 
age, diabetes duration, current HbA1c, historical HbA1c, current HbA1c (HbA1c-
above-target/HbA1c-within-target), and historical HbA1c (HbA1c-above-target/
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HbA1c-within-target) on SAF. We found no significant impact of gender on SAF. 
Adjusted R2 did not exceed 0.207. 
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Figure 3: Correlation between historical HbA1c and skin autofluorescence (SAF) in children and adoles-
cents with type 1 diabetes. 
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For the multiple linear regression analyses (Table 2), Model 1 showed a significant 
effect of ‘diabetes duration ≥ 10 years’ and age on SAF. In Model 2 the addition 
of the current HbA1c (HbA1c-above-target/HbA1c-within-target) and historical 
HbA1c (HbA1c-above-target/HbA1c-within-target) showed a significant impact 
of age and diabetes duration but not of current or historical HbA1c on SAF. The 
adjusted R2 increased to 0.235. 
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Table 2: Univariate and multiple linear regression analyses (n = 77) to assess the impact of the following 
covariables on SAF: age; diabetes duration; gender; current HbA1c (current value, and HbA1c-above-tar-
get/ HbA1c-within-target); and historical HbA1c (historical value, and HbA1c-above-target/ HbA1c-with-
in-target). 
HbA1c-above-target: > 7.5%/59 mmol/mol; HbA1c-within-target HbA1c: ≤ 7.5%/59 mmol/mol.
Beta  
coefficient 95% CI P-value Adjusted R2
Univariate analysis
Age (years) 0.047 0.026, 0.067 < 0.001 0.207
Duration of diabetes (years) 0.025 0.013, 0.038 < 0.001 0.172
Sex (male/female) 0.047 –0.056, 0.150 0.366 –0.002
Current HbA1c (%) 0.056 0.019, 0.092 0.003 0.097
Historical HbA1c (%) (n = 73) 0.057 0.003, 0.111 0.040 0.045
Current HbA1c: HbA1c-above-target vs. Hba1c-with-
in-target 0.034 -0.104, 0.172 0.628 -0.010
Historical HbA1c: HbA1c-above-target vs. 
Hba1c-within-target (n = 73) 0.028 -0.092, 0.147 0.645 -0.011
Multiple linear regression analysis 
Model 1 (n=77) 0.265
Age (years) 0.040 0.019, 0.061 < 0.001
Diabetes duration 4 to  
< 10 years vs. ≤ 4 years 0.065 –0.044, 0.172 0.239
Diabetes duration ≥ 10 years  
vs. ≤ 4 years 0.187 0.053, 0.320 0.007
Model 2 (n=73) 0.235
Age (years) 0.043 0.022, 0.065 < 0.001
Diabetes duration 4 to  
< 10 years vs. ≤ 4 years 0.056 –0.064, 0.175 0.356
Diabetes duration ≥ 10 years  
vs. ≤ 4 years 0.179 0.030, 0.328 0.019
Current HbA1c: HbA1c-above-target vs. Hba1c-with-
in-target 0.012 -0.138, 0.162 0.872
Historical HbA1c: HbA1c-above-target vs. 
Hba1c-within-target -0.048 –0.172, 0.077 0.446
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Discussion
Consistent with previous studies (12–14), patients with type 1 diabetes showed 
significantly higher SAF than controls, both for the group as a whole and across 
all age categories. It is important to note that this was already apparent for the 
lowest age category (age 11–12 years). SAF appeared to increase faster in the elder 
adolescents for both patients and controls and with diabetes duration in patients. 
Differences in SAF between current HbA1c-within-target and HbA1c-above-tar-
get patients and between historical HbA1c-within-target and HbA1c-above-tar-
get patients were small. In addition, SAF was only weakly associated with diabe-
tes duration and HbA1c (both current and historical) in our homogeneous group 
of Dutch Caucasians, consistent with findings from Felipe et al. (14). This associ-
ation disappeared when adjusting for diabetes duration and age. Interestingly, a 
subgroup of patients with a HbA1c-within-target had an elevated SAF. 
Previous studies showed conflicting results on the association between historical 
HbA1c and SAF (5, 21). A strong correlation between historical HbA1c and SAF 
would be expected, as SAF is believed to be at least partly caused by hyperglyce-
mia-induced superoxide and carbonyl damage, resulting in permanent damage 
to long-lived proteins such as collagen (3, 22). However, in this study, a strong 
association between historical HbA1c and SAF could not be demonstrated. An 
explanation may be that the period during which historical HbA1c was deter-
mined was too short or that median intra-individual HbA1c is an inadequate 
parameter to express historical HbA1c. Alternatively, as sAGEs are considered 
to be formed by various pathways (5, 22, 23), the influence of hyperglycemia on 
SAF may also be overestimated. It is intriguing to see that some patients show an 
elevated SAF despite having a HbA1c-within-target. This may be explained by ge-
netic factors influencing either the level of glycation of HbA1c or by factors that 
influence AGE formation such as polymorphisms of the AGE-receptor (RAGE) 
gene (24) or the NAT2 acetylator (25). Also, oxidative/carbonyl stress may play a 
role (23, 26), which may be hypoglycemia-related (27). An outstanding question 
is if this heterogeneity in patients reflects differences in risk for complications. If 
so, then SAF measurement in this subgroup may provide information on risk for 
complications independent of HbA1c.  
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A strength of this study was that adjustment for skin color was not necessary, as 
measured patients and controls were from the same ethnic background (Cauca-
sian). Homogeneity of the patient population supports internal validity. However, 
the results cannot be applied to non-Caucasians and therefore generalizability is 
lower. Also, we studied the age range 11–19 years in more detail when compared 
with previous studies (12, 14, 28), showing clearly that children and adolescents 
with type 1 diabetes in the age category 11–12 years already have elevated SAF. We 
took into account the use of skin care products, as these can affect SAF readings 
(29). One limitation of our study as well as previous studies (13,14) is that we were 
unable to quantify measurement errors in terms of coefficient of variation. To 
reduce measurement error as much as possible, only one type of AGE-reader 
was used and SAF measurements were performed in triplicate. However, when 
measuring SAF is to be of use in routine clinical practice, precision CV of these 
measurements will have to be assessed to be able to distinguish measurement 
error from clinically meaningful SAF measurements. SAF readings may be con-
founded by a number of behavioral factors such as dietary factors and fasting 
state (30). Additional factors such as smoking and exercise are implicated in the 
accumulation of SAF (20, 28). We could not adjust for these factors. BMI may 
influence SAF, in particular in individuals with central obesity (31). We did not 
extend the BMI analyses as only 4 patients had a BMI > +2 SDS. 
In summary, children and adolescents with type 1 diabetes show higher SAF 
than controls. Age and duration of diabetes are weakly associated with SAF. In 
e majority of patients, SAF does not seem to provide information additional to 
HbA1c. However, in a subgroup of patients with HbA1c-within-target an elevated 
SAF was observed . For this subgroup, measuring SAF may have added value in 
identifying patients that are at high risk for complications. Further longitudinal, 
prospective studies should provide insight into whether SAF measurement in 
youngsters has predictive value for the development of complications during the 
disease course of type 1 diabetes and how this is related to glycemic control.
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8.1 Introduction
The incidence of type 1 diabetes is still increasing (1-3). Despite advances in care 
and increasing knowledge about modifiable risk factors and potential interven-
tions (4-7), the incidence and prevalence of the microvascular (nephropathy, 
neuropathy and retinopathy) and macrovascular complications of diabetes are 
still substantially increased compared with the general population (8, 9). Tak-
ing into account that there are more determinants than those involved in the 
classical hyperglycaemia paradigm, two factors are thought to contribute to this 
worrisome perspective for patients with type 1 diabetes: 1) a lack of awareness 
of the impact of (certain) risk factors and 2) the suboptimal early detection of 
the high-risk patient, e.g. the patient with risk factors and/or early signs of com-
plications (10-12). We reasoned that improving the identification of children and 
adolescents with type 1 diabetes with (one or more) risk factors and/or early signs 
of complications, by improving early risk stratification, will allow adaptation of 
screening procedures and/or implementation of earlier interventions. This, in 
turn, would hopefully result in an improved lifetime perspective for the patients 
with type 1 diabetes. 
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8.1 Introduction
The incidence of type 1 diabetes is still increasing (1-3). Despite advances in care 
and increasing knowledge about modifiable risk factors and potential interven-
tions (4-7), the incidence and prevalence of the microvascular (nephropathy, 
neuropathy and retinopathy) and macrovascular complications of diabetes are 
still substantially increased compared with the general population (8, 9). Tak-
ing into account that there are more determinants than those involved in the 
classical hyperglycaemia paradigm, two factors are thought to contribute to this 
worrisome perspective for patients with type 1 diabetes: 1) a lack of awareness 
of the impact of (certain) risk factors and 2) the suboptimal early detection of 
the high-risk patient, e.g. the patient with risk factors and/or early signs of com-
plications (10-12). We reasoned that improving the identification of children and 
adolescents with type 1 diabetes with (one or more) risk factors and/or early signs 
of complications, by improving early risk stratification, will allow adaptation of 
screening procedures and/or implementation of earlier interventions. This, in 
turn, would hopefully result in an improved lifetime perspective for the patients 
with type 1 diabetes. 
The EDDDY-S study was conducted between 2007 and 2018 with the goal to 
improve this early risk stratification in children and adolescents with type 1 diabe-
tes. This study was designed to focus on areas in complication-related research 
underexposed in 2007 for this age-group and therefore does not cover tests in all 
complication fields. 
The Early Detection of Diabetes Damage in Youth and Search for early preven-
tion (EDDDY-S) study assessed:  
• the diagnostic value of two parameters for the detection of subclinical 
peripheral diabetic neuropathy (DPN): compound muscle action potential 
(CMAP) scan by CMAP scan of the peroneal motor nerve; and measure-
ment of nerve conduction velocity (NCV) and sensory nerve action poten-
tial (SNAP) of two sensory nerves by electrophysiologic tests (Chapters 2-4). 
• a surrogate marker for macrovascular complications: carotid intima media 
thickness (cIMT) by means of carotid ultrasound (Chapter 5).
• longitudinal lipid dynamics of patients with type 1 diabetes:  
predominantly the change to an unfavourable level (‘losing track of lipids’) 
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through childhood and adolescence was studied because dyslipidemia is a 
risk factor for macrovascular complications (Chapter 6).  
• a presumed surrogate marker for both micro- and macrovascular complica-
tions: assessment of skin autofluorescence (SAF) by measuring advanced 
glycation end products (AGEs) in the skin using the AGE-reader (Chapter 7).
 
The outline of this general discussion, in which we will further elaborate on early 
risk stratification in children and adolescents with type 1 diabetes, is as follows: 
in section 8.2 for each field of complication studied in the EDDDY-S study, the 
results will be summarized followed by a short review of the literature (Figure 1). 
After putting the results into context of the literature, feasibility for future use in 
a proposed screening protocol will be discussed. As this screening protocol would 
also include tests which are currently still in the research setting, we allocated 
the tests in the proposed screening protocol to one of the following 3 parameter 
categories:  
A. tests included in the recommendations according to international guidelines 
(13, 14) and as such in general assumed to be established diagnostic tests
B. diagnostic tests other than the ones recommended in the current guidelines
C. tests in research context
After some methodological considerations in section 8.3, we conclude the 
general discussion with integrating our proposals for screening into a suggested 
screening protocol in section 8.4. 
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8.2 Summary and implications of results from the 
EDDDY-S study
Two tests for diabetic peripheral neuropathy (DPN)
 
EDDDY-S 
Large nerve fiber dysfunction is a presumed late(r) sign of DPN (15, 16). Because 
screening recommended in the guideline of 2007 (17) predominantly tests for 
large nerve fiber dysfunction, two pilot-studies of the EDDDY-S study assessed 
the detection of subclinical DPN. One pilot study measured the nerve conduc-
tion velocity (NCV) and sensory nerve action potential (SNAP) amplitude of 
two sensory nerves, investigating if the frequently-used reference test for DPN 
(electrophysiologic study of the NCV) indeed fails to detect subclinical DPN. In 
the other pilot study, several variables of the novel compound muscle action po-
tential (CMAP) scan were measured in the peroneal motor nerve. The first pilot 
study showed that neither the NCV nor the SNAP amplitude of the two sensory 
nerves did accurately detect subclinical DPN in the children and adolescents with 
type 1 diabetes. The second pilot study showed the CMAP-variable ‘stimulus 
intensity’ (reflecting axonal excitability) to be abnormal in both young patients 
with well-controlled type 1 diabetes and a relatively short disease duration, and 
in patients with poorly controlled type 1 diabetes and quite long disease duration, 
when compared with healthy controls. We therefore conclude that the CMAP 
scan is a promising test for the detection of early DPN.
2007-2018
Small nerve fiber dysfunction as measure of subclinical DPN is typically per-
formed by measuring corneal nerve fiber density (CNFD) and corneal nerve 
fiber branch density (CNFBD) by corneal confocal microscopy (CCM). In adult 
patients with type 1 diabetes, CNFD and CNFBD were shown to correlate with 
intra-epidermal nerve fiber (branch) density in skin biopsies (reference test) 
(18). Associations between several corneal nerve measurements and severity of 
clinical DPN (18-20), other small nerve fiber function tests (18, 21) and the devel-
opment of future DPN (22) were found. In children and adolescents with type 
1 diabetes, only one study was performed. In this pilot study, no difference was 
found in corneal confocal microscopy (CCM) measures between adolescents 
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with type 1 diabetes (n=6) and healthy age-matched controls (23), perhaps due 
to small sample size. 
Screening tests for the detection of large nerve fiber dysfunction were evaluated 
as well (24). Determination of the vibration perception threshold (VPT), by the 
Biothesiometer or Vibratory Sensory Analyser, appeared to have a better diag-
nostic utility in detecting subclinical DPN in children and adolescents with type 1 
diabetes than the tuning fork or Vibratron II (24-27). Evaluation of the diagnostic 
value of testing the tactile function with smaller monofilaments (1 mN) showed 
controversial results (16, 24, 28). The debate on the diagnostic value of electro-
physiologic studies in detecting subclinical DPN continued. A small percentage 
of patients with clinical DPN at young adult age had an impaired peroneal and 
median motor nerve conduction velocity and/or sural sensory nerve action 
potential at baseline (mean age at baseline 15.5 years)(29). Hyperglycaemie was 
suggested to affect nerve conduction velocity but not sensory nerve action 
potential when present during electrophysiologic testing (30) in contrary to a 
previous study on this subject (31). 
Finally, several studies evaluated the diagnostic value in detecting subclinical 
DPN of CCM and/or other small nerve fiber function tests such as quantitative 
sensory testing together with or compared with large fiber function tests (22, 32). 
In adults with type 1 diabetes, Breiner and Pritchard showed one or more small 
nerve fiber function tests to be abnormal in case of (future development of) ab-
normal large nerve fiber function (22, 33). However, these studies, did not show 
that small nerve fiber dysfunction per se precedes large nerve fiber dysfunction. 
In children, adolescents and young adults with type 1 diabetes, only cross-sec-
tional studies were performed. VPTs (large nerve fiber) by means of Biothesiom-
eter/ Vibratory Sensory Analyser and/or thermal thresholds (small nerve fibers) 
by means of Thermal Threshold Tester/ Neurosensory TSA-II were shown to be 
abnormal, and thus suggested to detect subclinical DPN, in 14-28% of the chil-
dren and adolescents with type 1 diabetes (25, 26). It was not specified which 
of the two performed tests were abnormal in their patient group. Weintrob and 
Blankenburg showed that more young adults and adolescents with type 1 diabe-
tes had small nerve fiber dysfunction then large nerve fiber dysfunction (32, 34). 
However, both studies do not show if the patients with large nerve fiber dysfunc-
tion had small nerve fiber as well, which would have strengthened the hypothesis 
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Figure 1: Promising tests between 2007-2018 studying some underexposed areas in complication-related 
research in pediatric diabetes and tests in these areas that were included in the EDDDY-S study (with in 
bold most promising tests). 
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of small nerve fiber dysfunction preceding dysfunction of the large nerve fibers. 
Additionally, longitudinal data are lacking. 
Thus, at present it remains to be elucidated if the preferred approach in detecting 
subclinical DPN appropriately in children and adolescents with type 1 diabetes 
should include only (one of the) small nerve fiber function tests, or a combination 
of large and small nerve fiber function tests.  
Implications
Our research showed a low diagnostic value of measurement of the sensory NCV 
and SNAP amplitude for the detection of subclinical DPN in children and ado-
lescents with type 1 diabetes. Despite the small study population, we predicted 
that a larger sample is unlikely to alter this main conclusion. Whereas these study 
results strengthen the idea and that of others that more focus on other nerve 
fibers than the large nerve fibers (only) is indicated in the development of screen-
ing tests for subclinical DPN, recent studies suggested that measurement of the 
VPT by Biothesiometer/ Vibratory Sensory Analyser detects subclinical DPN and 
thus inclusion of this test should be considered as subject of the screening pro-
tocol. In addition, the CMAP scan study results showed that another approach 
to large nerve fiber damage, e.g. focus on axonal damage, may also be helpful in 
the detection of subclinical DPN. New scientific insights from 2007 to 2018 show 
that more focus on small fiber nerve function should be considered as part of the 
screening protocol for subclinical DPN as well. CCM appears most promising. 
Our ultimate goal is that the screening protocol for children and adolescents 
with type 1 diabetes includes one screening test for subclinical DPN. However, 
with the current paucity of studies that assess promising screening tests based 
on determination of the VPT by Biothesiometer/ Vibratory Sensory Analyser, the 
CMAP scan and CCM, we propose to study these three tests in a combined diag-
nostic and research screening protocol. We allocate the VPT by Biothesiometer/ 
Vibratory Sensory Analyser to category B because abnormal VPT has been found 
in type 1 diabetes in several pediatric studies (24-26). We allocate measurement 
of stimulus intensities of the peroneal nerve by the CMAP scan and CNFD and 
CNFBD by CCM to parameter category C because there is not much experience 
yet with both tests in pediatrics.
131
General discussion
Carotid intima media thickness (cIMT)
EDDDY-S
cIMT is considered to be a surrogate marker of subclinical atherosclerosis and 
associated with macrovascular complications (35-37). It gained our attention be-
cause a surrogate marker and/or early sign for macrovascular complications was 
lacking in the childhood and adolescent age-group with type 1 diabetes. In 2007, 
the existing studies on this subject showed controversial results on cIMT increase 
in children and adolescents with type 1 diabetes compared with healthy controls 
and on the impact of contributing factors to cIMT increase (38-40). Additionally, 
information about age-specific differences between children and adolescents 
with type 1 diabetes and their peers was lacking (38-40). Across all age categories 
we found cIMT to be equally increased in patients with type 1 diabetes compared 
with healthy controls, i.e. to already be abnormal in the youngest age category 
(9-10 years old). No significant contribution of poor glycaemic control and other 
classical risk factors was found. 
2007-2018 
Several studies showed cIMT to be increased in children and adolescents with 
type 1 diabetes as compared with healthy peers (38, 41, 42). cIMT progression 
was detected in high-risk patients within only a short follow up period (41, 43). 
Controversially, a review of observational studies showed that cIMT is not always 
increased in pediatric patients with type 1 diabetes when compared with healthy 
controls (44). Small study populations, young age, a short duration of diabe-
tes (and thus short follow-up) were suggested as explanations, in addition to 
more general comments such as wide reference ranges for cIMT in children and 
adolescents and the heterogeneity in cIMT study protocols (44). Several studies 
suggested aortic IMT (aIMT) to be a more sensitive surrogate marker for subclin-
ical atherosclerosis  (35, 45-48). However, replacing cIMT by aIMT measurement 
is questionable because measuring aIMT is suggested to be more difficult in case 
of increased tissue penetrance and takes more time (46-48). 
Endothelial function was measured by flow-mediated dilation (FMD) of the 
brachial artery as a result of reactive hyperaemia after shear stress using different 
techniques. In children and adolescents with type 1 diabetes, FMD was shown 
to be abnormal when compared with healthy controls (48-52). Associations 
132
Chapter 8
with HbA1c and microalbuminuria were found (49, 51, 52). Despite FMD being a 
non-invasive objective measure of endothelial function, the required conditions 
of measurement in a regulated room temperature (48-50), the possible influence 
of acute hyperglycaemia on FMD (50, 53) and the absence of pediatric reference 
ranges, makes its implementation in routine outpatient care challenging.
Several measures for arterial stiffness, such as small artery elasticity (SAE), 
pulse pressure (PP), pulse wave velocity (PWV), augmentation index (A175) and 
brachial distensibility (BrachD) were studied between 2007-2018. An earlier SAE 
peak in life, a diminished SAE and an increased PP beyond the age of 30-40 years 
old was found in patients with type 1 diabetes and complications as compared 
with the other patients without complications and healthy controls (54). Another 
study found an increased PP already in childhood in patients with type 1 diabetes 
(55). PWV was shown to increase throughout adolescence in patients with type 
1 diabetes (56), whereas two studies comparing PWV to reference ranges found 
contrary results (57, 58). One of these studies evaluated A175 and BrachD as well 
and found both to be abnormal in the patients with type 1 diabetes when com-
pared with healthy controls (58, 59). Reference values for European children and 
adolescents have been determined for PWV (60), PP (61) and SAE (62). To our 
knowledge, reference values of augmentation index (A175) and a diminished bra-
chial distensibility have not been established yet. Less accurate measurement of 
PP and PWC have been suggested in case of a very young age and an increased 
waist circumference respectively (56, 57). 
Implications
cIMT has been clearly shown to be abnormal in children and adolescents with 
type 1 diabetes (38, 40-43, 63). Appropriate reference ranges are available (63). 
Also taking into account the shown associations of increased cIMT and macro-
vascular complications (36, 37), we think cIMT should be included in the future 
screening protocol (parameter category B). Due to a lack of  appropriate refer-
ence ranges and the incapability of measuring aIMT in case of obesity, aIMT will 
not be added although it might show abnormalities earlier than cIMT. Abnormal 
PP and PWV, reflecting increased arterial stiffness, are both promising surrogate 
markers for macrovascular complications. We hypothesize these markers to 
replace the cIMT measurement because both tests are less observer-dependent 
and easily applicable in the outpatient clinic patient care. Reference ranges are 
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available (60, 61). Because there is not enough experience with these tests in 
the pediatric age group, we allocate PP and PWV to parameter category C. We 
propose to include both cIMT and PP and PWV in a proposed screening proto-
col. Future evaluation of the three presumed surrogate markers in this screening 
protocol should address if PP and/or PWV can replace cIMT measurement.    
Longitudinal lipid dynamics
EDDDY-S
The values of low-density lipoprotein cholesterol (LDL-C), high-density lipo-
protein cholesterol (HDL-C), total cholesterol (TC) and triglycerides (TG) of 
healthy children and adolescents are shown to be quite stable from childhood 
through young adulthood (64). A longitudinal study by Maahs evaluated the dy-
namics of these lipids and of non-HDL cholesterol (non-HDL-C) in children and 
adolescents with type 1 diabetes (65). This study showed that a considerable pro-
portion of patients changed from a low-risk lipid level into a borderline-high risk 
or high-risk level or changed from a borderline-high risk level into a high-risk level 
of lipids (‘lose track of lipids’). As dyslipidemia is a known risk factor for macro-
vascular complications, detection of patients that lose track of lipids is important. 
Our retrospective longitudinal study, including 651 children and adolescents with 
type 1 diabetes, studied the dynamics of LDL-C, HDL-C, non-HDL-C, TC and 
TG and showed that a considerable number of the patients switched to border-
line-high risk or high-risk levels of >1 of the studied lipids within a median follow 
up duration of 3.24 years. Of the patients with a LDL-C or HDL-C low-risk level at 
baseline, 5-10% lost track of these lipids within a screening interval of two years. 
With regard to the other lipid parameters, 25-30% lost track of lipids. The use of 
a prognostic index, including age, gender, BMI and HbA1c, diabetes duration and 
ethnicity, was only moderately able to predict this change on the short term.  
2007-2018
In addition to the early studies of Maahs (65) and Edge (66), more recent studies 
strengthen the finding that children and adolescents with type 1 diabetes ‘lose 
track of lipids’ (67-69) and show predominantly the determinants HbA1c and 
BMI to influence lipid dynamics (65, 67, 68). Additionally, several cross-sectional 
studies in this age-group with type 1 diabetes showed added value in risk strati-
fication of extending the lipid profile (LDL-C, HDL-C, non-HDL-C, TC and TG) 
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with lipids such as apolipoprotein B and LDL-C particle size that are supposed to 
inform better about the atherogenicity (70-72).
Implications
Our longitudinal study in lipid dynamics together with study of the literature 
2007-2018 showed that inclusion of apoB, among others, can be of additional 
value in interpreting the lipid profile. Therefore, we suggest to add apoB to the 
lipid screening protocol (parameter category B). It also revealed that 5% of the 
patients lost track of non-HDL-C levels within 16.5 months; TC levels within 13.5 
months; and TG levels within 13 months. This was in contrast with 22 months for 
LDL-C and 20 months for HDL-C. With conventional treatment of dyslipidemia 
focussing on LDL-C in this age group (10, 14), we suggest to continue the 2 year 
lipid screening protocol (parameter category B). Future study should address if 
this interval should be adapted to the losing track of one of the other fore men-
tioned lipids, but only if relevant treatment options exist. Whereas our tracking 
study only showed moderate power of a combination of several determinants in 
predicting losing track of lipids on the short term, one or more of those determi-
nants were shown to predict losing track of lipids if used separately in other stud-
ies (65, 67, 68). We propose to study the impact of the determinants age, gender, 
HbA1c, BMI, ethnicity and diabetes duration, separately and in combinations, on 
the likelihood of losing track of lipids. Additionally we suggest to study the impact 
of other determinants such as smoking, puberty, non-alcoholic fatty liver disease 
and positive family history of premature cardiovascular disease on the likelihood 
of losing track of lipids.
Advanced glycation end products (AGEs) in skin
EDDDY-S 
Advanced glycation end products (AGEs) in the skin, measured by skin autoflu-
orescence (SAF), were shown to associate with both micro- and macrovascular 
complications in adults with type 1 diabetes and therefore appeared a promising 
surrogate marker for these complications (73, 74). In 2007, measurement of SAF 
had not yet been performed in children and adolescents with type 1 diabetes. 
In the EDDDY-S study, SAF was shown to be elevated similarly across all age 
categories in the patients with type 1 diabetes, i.e. also in the youngest age group 
already (11-12 years). Glycaemic control was not shown to associate with SAF ele-
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vation. Interestingly, a subgroup of patients showed increased SAF despite having 
good glycaemic control. 
2007-2018
AGE levels were determined by skin autofluorescence (SAF) or skin intrinsic 
fluorescence (SIF) in several studies in the period 2007-2018 (75-78). In adults 
with type 1 diabetes, previously found associations between increased SAF/SIF 
and the prevalence of micro- and macrovascular complications were confirmed 
(75-77, 79, 80). In children and adolescents with type 1 diabetes, SAF/SIF were 
shown to be increased in this age-group when compared with healthy controls 
(45, 81-83). Associations of SAF/SIF with early signs of micro- and macrovas-
cular complications in this age-group were shown with regard to retinopathy, a 
measure of heart rate variability and aIMT, but not with peripheral nerve abnor-
malities and albumin excretion rate or glomerular filtration rate (26, 45). Studies 
that examined correlations between SAF/SIF and (long-term) HbA1c showed 
conflicting results (26, 75, 77, 78, 80, 84, 85). Moreover, increased SAF/SIF was 
already shown in children that were just recently (< 1 week) diagnosed with type 1 
diabetes (82) and was shown to be present in a subgroup of patients with normal 
HbA1c levels (26, 78). 
Implications
Measuring SAF is a presumed surrogate marker for micro- and macrovascular 
complications in patients with type 1 diabetes (73-77, 79, 80, 86, 87). With con-
troversial results on long-term HbA1c and SAF and a subgroup of patients show-
ing elevated SAF despite appropriate (long-term) glycaemic control, it remains 
to be elucidated if SAF is of additional value to HbA1c in predicting micro-and 
macrovascular complications. Future studies should show if HbA1c and SAF can 
be interchangeable surrogate markers for the average patient, but also if SAF is 
a better surrogate marker in a subgroup of patients. Longitudinal prospective 
studies, starting SAF measurement at diagnosis of type 1 diabetes, followed by 
3-monthly measurements (parameter category C) combined with simultane-
ous assessment of (early) signs of complications at regular intervals, should help 
answering the following outstanding issues: 
• The intrapersonal variability of SAF over a relatively short period of time, 
possibly explained by confounding factors such as dietary factors, fasting and 
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smoking the day before measurement (88-91), or an association with short-
term glycaemic control or other glucose related measures (such as glucose 
variability). 
• What should become the future SAF measurement scheme, e.g. which SAF 
measurement(s) in the scheme associate best with (early) signs of long-term 
complications?
• Does SAF indeed identify a subgroup of patients that develop (early) signs of 
complications despite appropriate glycaemic control? Moreover, are regular 
SAF instead of HbA1c measurements warranted for these patients? 
The EDDDY-S study reveals two intriguing findings that need further study:
Firstly, in at least a subgroup of children and adolescents with type 1 diabetes, 
glycaemic control was not a contributor to the development of complications; no 
significant contribution of HbA1c to the increase in cIMT was found; a subgroup 
of patients had an elevated SAF despite an HbA1c < 7.5% (58 mmol/mol); de-
creased axonal excitability in a patient-group with well-controlled diabetes was 
shown; and HbA1c did not contribute to ‘losing track of lipids’ for LDL-C, HDL-C, 
non-HDL-C, TC and TG, possibly due to heterogeneity in the patient group. 
There is overwhelming evidence to suggest that poor glycaemic control (i.e. high 
HbA1c) is a dominant risk factor for the development of complications in the 
entire cohort of patient with type 1 diabetes (4-6, 8, 92-98). However, this may 
not be the case for the individual patient. In the EDDDY-S study we showed that 
poor glycaemic control did not contribute significantly to decreased axonal ex-
citability, cIMT increase, elevation of SAF, and only moderately to losing track of 
lipids (Chapters 2,5,6 and 7). The EDDDY-S study is not the only study that takes 
a more individualized approach. Cho showed a higher prevalence of sub-clinical 
retinopathy in adolescents with type 1 diabetes with well-controlled diabetes but 
increased SAF in the highest tertile (26), whereas Lilje did not find an association 
between elevated skin intrinsic fluorescence (SIF), poor glycaemic control and 
increased aortic intima-media thickness (45). Appropriate glycaemic control 
may have mitigated the (relative) contribution to study results in the EDDDY-S 
study. The findings in our study and the Cho and Lilje studies may be explained 
by heterogeneity among patients with type 1 diabetes for at least a proportion 
of the patients. There might be a subgroup of patients that will never develop 
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complications and a subgroup of patients that will develop complications despite 
good glycaemic control. We do indeed think such subgroups exist. Alternatively, 
other established risk factors not included in these studies (5, 8, 9, 40, 93-95, 99-
107), or yet unidentified risk factors may play a role and their effects may (partly) 
overrule the effect of glycaemic control on complications. 
In the last few years, the relevance of heterogeneity among patients with diabe-
tes has gained more attention. Heterogeneity in the disease diabetes is thought 
to be caused by, among others, genetic and environmental factors, which not 
only affect the course of the disease and its subtypes(108-110), but will also pose 
different risks for the development and/or progression of complications (11, 111).  
Presumable risk factors that may diminish the (relative) contribution of HbA1c to 
the development of complications are listed in Table 1. 
Table 1: Risk factors described to increase complication risk in type 1 diabetes
The presence of certain inflammation markers (112, 113)
Less pre-diabetes beta cell mass (originated in utero, environmentally or genetically) (114)
Increased beta cell vulnerability to the auto-immune attack (114)
More biological variation in HbA1c, measured by haemoglobin glycation index (115)
Genotypes related to presence or development of risk factors (116-120)
Unfavourable microRNA expression (121)
Increased dysregulation of epigenetic mechanisms (122)
Influence of ‘metabolic memory’ related to the timing of hyperglycaemia in the 
course of the disease (123, 124)
The influence of glucagon to glucose homeostasis (125)
Secondly, a considerable number of patients with type 1 diabetes developed 
subclinical complications already in childhood and adolescence: signs of subclin-
ical atherosclerosis, assessed by cIMT measurement, were observed in patients 
as young as 9-10 years; subclinical DPN was found to be present in patients with 
a median age of 13.92 years; and SAF elevation could be seen in the youngest age 
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category e.g. 11-12 years already. As SAF is assumed to be a surrogate marker for 
micro- and macrovascular complications (at least in adults with type 1 diabetes), 
this finding strengthens the idea that detectable (early signs of) complications 
may already develop at a young age. However, future longitudinal studies should 
assess if these parameters can indeed function as surrogate markers. These 
studies should also address if the parameters can identify a subgroup of patients 
that behaves differently compared with the type 1 diabetes group as a whole, i.e. 
reflect heterogeneity. 
In the period 2007-2018 several studies investigating early signs of complications in 
children and adolescents with type 1 diabetes supported the EDDDY-S study find-
ings. Clinical DPN and subclinical DPN, subclinical retinopathy, nephropathy and 
macrovascular complications were found in children and young adolescents with 
type 1 diabetes by several investigators (Table 2 and Appendix 2)(25, 26, 34, 45, 54, 
55, 126) stressing the need for sensitive tests for the young age group. 
Table 2: Data from EDDDY-S sub-studies and comparable studies about surrogate markers and subclinical 
complications in children and adolescents with type 1 diabetes 
 
A: Compound muscle action potential (CMAP) scan (early sign of diabetic peripheral neuropathy) 
 
Van der Heyden 2013(127) (n=30)
Age (yrs) Pt-group 1 (n=13): 13.9 (12.6-17.1)Pt-group 2 (n=17): 18.8 yr (15.9-22.4)
Diabetes duration (yrs) Pt-group 1: 3.8 (3.5-4.5)Pt-group 2: 12.6 (11.4-16.5) 
HbA1c (%) Pt-group 1: 7.1 (6.9-7.6)Pt-group 2: 9.2 (8.4-10.4)
Outcome variables measured by 
means of CMAP scan in short
Decreased axonal excitability in patients 
compared with controls
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B: Nerve conduction velocity and sensory action potential of sensory nerves (early sign of diabetic 
peripheral neuropathy) 
 
 
Van der Heyden, unpub-
lished (n=20)
Hyllienmark 
1995(128) 
(n=75)
Riihimaa 
2001(100) 
(n=100)
Nelson 
2006(27) 
(n=73)
Age (yrs) Pt-group 1: 14.0 (13.7-17.3)Pt-group 2: 16.4 (13.7-18.5) 15.4 (3.6) 13.7 (2.0) 13.7 (2.6)
Diabetes dura-
tion (yrs)
Pt-group 1: 3.8 (3.4-4.4)
Pt-group 2: 12.1 (10.6-13.7) 8.2 (3.5) 7.0 (3.5) 8.1 (2.6)
HbA1c (%) Pt-group 1: 7.3 (7.0-7.7)Pt-group 2: 9.4 (8.9-11.2) 7.0 (1.1) 8.5 (1.7) 9.0 (1.0)
Outcome NCV, 
SNAP 
No difference in NCV 
between groups. SNAP
amplitude decreased 
in Pt-group 2 (poorly 
controlled patients) 
compared with controls
Decreased 
NCV and 
SNAP of sen-
sory sural and 
median nerve 
in patients 
compared 
with controls
Decreased 
NCV and 
SNAP of 
sensory sural 
and median 
nerve in 
patients 
compared 
with controls
Considerable 
number of 
patients with 
decreased 
NCV of sural 
nerve and 
small number 
with de-
creased SNAP, 
compared 
with controls
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C: Carotid intima media thickness (surrogate marker and/or early sign of macrovascular disease)
Van der Heyden 2016 
(63)
 n=135
Lilje 
2018(45)
n=38
Schwab 
2007(38)
n=94
Dalla Pozza 
2007 (40) 
n=150
Margeirsdottir 
2010 (42)  
n=314
Age (yrs) 15.3 (13.4-18.2) 13.4 (3.4) 12.3 (8.5-16.8) 13.9 (2.8) 13.8 (2.8)
Diabetes  
duration 
(yrs)
After stratification
by age 15.3 or ≥15.3 
years: 5.6 (3.8-8.3) 
and 10.0 (6.3-14.0) 
respectively
5.8 (4.3) 3.8 (1.8-9.8)
Not 
mentioned 
for the Pt-
group as a 
whole
5.5 (3.4)
HbA1c 
(%)
After stratification
by age 15.3 or ≥15.3 
years: 8.0 (7.4-8.7) and 
8.4 (7.5-9.2) respec-
tively
9.7 (1.6) 7.7 (6.8-10.0)
Male 7.5 
(0.9),
Female 7.4 
(0.9)
8.4 (1.3)
Outcome 
cIMT
cIMT increased in 
patients compared 
with controls
No 
significant 
difference 
between 
patients 
and 
controls in 
cIMT: only 
in aIMT 
and fIMT
cIMT 
increased 
in patients 
compared 
with controls
cIMT 
increased 
in patients 
compared 
with con-
trols
No significant 
difference be-
tween patients 
and controls; 
higher percent-
age of abnormal 
cIMT in the 
Pt-group
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D
: Longitudinal tracking of lipids (risk factor for m
acrovascular disease)
Van der H
eyden, 
subm
itted 2018 
(n=651)
M
aahs 
2007(65) 
(n=360)
Edge 2008(66) 
(n=229)
Reh 2011(67) 
(n=46)
Katz 2017(68) 
(n=572)
Shah 2017(69) 
(n=1478)
A
ge (yr) at baseline
12.63 (4.6)
13.6 (4.1)
12.4 (3.2)
14.3 (3.4)
11.9 (2.9)
10.8 (3.9)
D
iabetes duration (yr)
4.05 (2.1-7.2)
4.5 (0.3)
5.5 (4.0)
6.4 (3.8)
4.8 (3.1)
0.75 (0.5) 
H
bA
1c (%
)
7.7 (7.0-8.6)
8.8 (1.6)
8.8 (1.4)
8.1 (1.0)
8.9 (1.5)
7.6 (1.5)
O
utcom
e lipid tracking 
in short
A considerable 
num
ber of 
patients loses 
track
A considerable 
num
ber of 
patients loses 
track
A consider-
able num
ber 
of patients 
loses track
A considerable  
num
ber of 
patients loses 
track
Percentage of 
losing track not 
exam
ined
A consider-
able num
ber 
of patients 
loses track
142
Chapter 8
E: Skin autofluorescence (SAF) or skin intrinsic fluorescence (SIF) (surrogate marker for micro- and mac-
rovascular complications)
Van der Heyden 
2016(129) (n=77)
Cho 2017(26)
(n=135)
Lilje 2018(45)
(n=38)
Barat 
2012(83)
(n=52)
Shah 
2013(81)
(n=133)
Age (yrs) 15.3 (13.6-17.0) 15.6 (2.1) 13.4 (3.4) 12 (6) 13.0 (3.0)
Diabetes  
duration (yrs) 6.6 (3.5-9.5) 8.7 (3.5) 5.8 (4.3) 5.92 (3.8) 6.0 (3.6)
HbA1c (%) 8.5 (1.4) 8.7 (1.5) 9.7 (1.6) 8.0 (1.1) 9.3 (2.0)
Outcome SAF/
SIF in short
SAF increased 
in patients 
compared with 
controls
SAF 
increased 
in patients 
compared 
with con-
trols
SIF 
increased 
in patients 
compared 
with controls
SAF 
increased 
in 
patients 
com-
pared 
with 
controls
SIF 
increased 
in patients 
compared 
with con-
trols
Data expressed in median and interquartile range or mean and standard deviation and in the study of 
Schwab 68.5% CI Abbreviations: aIMT= aortic intima media thickness, cIMT= carotid intima media thick-
ness, CMAP= compound muscle action potential, fIMT=femoral intima media thickness, Pt=patient,  
SAF= skin autofluorescence, SIF= skin intrinsic fluorescence (SIF), NCV = nerve conduction velocity, 
SNAP = sensory nerve action potential
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8.3 Methodological considerations of the  
EDDDY-S study
Evaluating the EDDDY-S study as a whole, a few methodological issues should be 
addressed: 
• sample size and study duration, 
• the terminology of the used terms ‘risk factor’, ‘surrogate marker’, ‘early sign 
of complication’, ‘complication’, 
• the absence of reference tests, 
• use of data extracted from electronic databases, 
• possibilities and limitations to generalize results to the ‘general type 1  
diabetes population’.  
Sample size and study duration
Whereas sample sizes in the cross-sectional SAF and cIMT studies (Chapter 5 
and 7) were comparable to several published studies in children and adolescents 
with type 1 diabetes (26, 38-40, 78, 85), small sample sizes in the NCV/SNAP and 
CMAP scan studies (Chapter 2 and 3) were the result of the explorative nature of 
the study design, complexity of the techniques and strict inclusion criteria.  
The sample size of the longitudinal lipid tracking study (Chapter 6) was large for 
a single-centred European study in children and adolescents with type 1 diabetes. 
However, despite the local protocol that measures lipids every 2 years instead of 
every 5 years (17), the sample size decreased with increasing follow up duration. 
Comparable studies with approximately a similar study design (65, 66) encoun-
tered the same problems. The follow up of Shah’s study was longer but included 
patients with a shorter disease duration at baseline (69). We think the need for 
more longitudinal lipid studies is stressed by 1) recent growing awareness of the 
presence of modifiable risk factors that appear to be present already in childhood 
and adolescence, and 2) the possibility to prevent further deterioration if inter-
vention is initiated (10, 14, 130, 131). 
In general, small sample size poses two risks: potential lack of power and risk of 
selection bias. The first risk could not be mitigated in our studies. With regard 
to the second risk we compared our study population with study populations 
described in the literature, but could not completely rule out this risk. Overall, our 
study population compares relatively well with similar studies, although we report 
slightly better HbA1c levels and different ethnic composition (65, 66).
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Terminology
In the literature we found that in the field of complication research many terms 
are used interchangeably. Especially with respect to AGEs, some express eleva-
tion of SAF as risk factor while others use it as surrogate marker for micro- and 
macrovascular disease. We advocate using these terms as suggested below and 
in Figure 2.
• Risk factor: each determinant in a determinant-endpoint relationship
• Surrogate marker (132): a substitute of a clinical endpoint which is associated 
with that endpoint or prognostic of that endpoint 
• Early sign of complication: preclinical and/or clinical abnormality that may 
progress to a complication e.g. endpoint
• Complication: clinical condition with medical /personal consequences and 
requiring treatment and/or medication and/or intensive follow-up
 
 
Figure 2: Illustration of the current liftetime perspective of one patient in red. The expected change in 
lifetime perspective, based on an alarming result of a surrogate marker described in this thesis, is shown in 
blue.  
5 180
24 4030
40
Diagnosis: 
Type 1 diabetes
Years
Years
Risk 
factors
Complication: 
cardiac arrest
Surrogate
 marker
Changed
 lifestyle
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Absence of reference tests
The absence of a good short term reference test (e.g. reduction in intra-epider-
mal nerve fiber density by means of skin biopsy in case of subclinical DPN) in 
many of the subjects that were studied in this thesis and previous studies compli-
cates research in this field. In fact, in DPN, impaired NCV of the sensory nerve is 
frequently used as reference test (24, 27, 28). Determination of intra-epidermal 
fiber density by skin biopsy (133, 134) or myelinated fiber density examination 
by biopsy of the sural nerve may be a more appropriate reference test (135), but 
this method is too invasive to be used in a young age group (136). For skin AGEs, 
biopsies for studying collagen were also not easily to obtain. Meerwaldt et al had 
biopsies available and showed them to correlate with skin autofluoresence (137). 
In the field of vascular research, to the best of our knowledge the association be-
tween atherosclerosis and macrovascular disease is most convincingly support-
ed by post mortem data  combined with data on risk factors of macrovascular 
disease (35) and a long-term study showing thickening of the intima-media and 
plaque formation to associate with macrovascular disease (36). 
Data extracted from electronic database
Our studies were based on patient data extracted from the electronic patient 
files. In a recent review, Farmer discussed a number of potential problems using 
data from patient files for research purposes (138). Three problem-categories 
are described; 1) omitted variables; 2) incomplete data, missing data or data with 
unclear validity; and 3) time-related biases in case of follow up studies. 
For the EDDDY-S study examples of omitted variables (e.g. smoking and physical 
activity) were discussed in the lipid tracking and cIMT manuscripts (Chapter 5 
and 6). However, it was also reasoned that a strong impact of these factors on 
outcome is not to be expected. 
As an example of incomplete data, missing data or data with unclear validity, the 
incomplete data regarding positive family history for premature cardiovascular 
disease (CVD) can be considered. Although we did update family history for 
premature CVD in the cIMT study (Chapter 5), we did not do this for the track-
ing study (Chapter 6). As a result this possible determinant was excluded in the 
tracking study. 
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An example of time related biases includes the change and progression of 
the disease diabetes and its treatment. Factors such as insulin administration 
scheme, family history for premature CVD and smoking need regular reassess-
ment, without deleting previous data. Except for the updated family history on 
premature CVD in the cIMT study, these factors were, partly for this reason, not 
included in the other studies of the EDDDY-S study. 
Generalizing results to the ‘general type 1 diabetes population’. 
A potential problem with generalisation of the results is the difference in com-
position between European and American study groups. It is known that they 
differ in factors such as access to healthcare, lifestyle patterns and genetic back-
ground. Additionally, our well-regulated (in terms of HbA1c) study-population 
may potentially be not comparable with less optimally-regulated populations. 
Finally, as suggested in this thesis and by others, the heterogeneity in the disease 
diabetes itself seriously complicates generalisation of our study results.
8.4 Conclusion and further steps 
Evaluating the results of the EDDDY-S study, taking into account scientific 
insights in the period 2007-2018, we propose setting up a screening protocol 
for detection of risk factors and surrogate markers for (early) complications in 
children and adolescents with type 1 diabetes. As evidence of definite better, 
alternative tests or screening intervals is still scarce, it is suggested to continue 
following the current ISPAD screening protocol (13) for risk factors for micro- 
and macrovascular complications and (early) signs of those complications for 
children and adolescents with type 1 diabetes. 
However, the proposed screening protocol should additionally be based on sci-
entific insights from 2007 to 2018 in the discussed complication fields and find-
ings from the EDDDY-S study. It should include routine diagnostic tests but also 
tests which are still in the research setting (Figure 3). All tests should be selected 
on solid test characteristics and some practical considerations, e.g. they should 
be easily applicable in the outpatient clinic setting, patient-friendly and non-in-
vasive. Other new tests were reported between 2007 and 2018. However, since 
these are outside of the scope of this thesis we will discuss these in Appendix 2. 
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Therefore the proposed screening protocol only includes the complication fields 
examined in the EDDDY-S study.
Applying the proposed screening protocol would also enable addressing a 
number of outstanding research questions, for example on spatial and temporal 
relationships of the occurrence and progression of complications. Whereas there 
is scarce information about the longitudinal course of subclinical DPN that can 
be detected in a proportion of patients 2-3 weeks after diagnosis of type 1 diabe-
tes (139), there is even less information about the course of other measures which 
are also found to be abnormal after diagnosis, such as SAF (82). For this reason, 
we propose to initiate assessing several tests 3 months after the diagnosis of type 
1 diabetes. Thereafter, testing should be performed simultaneously at a 2- year 
interval (except for SAF). After a period of 6 years (i.e. three 2-year intervals), we 
suggest to evaluate the findings of these simultaneous measurements, expecting 
to be able to draw conclusions about the validity of the tests that were performed 
in the research context and to limit the number of currently proposed tests to 
a subset(s) of tests able to identify patients at risk of developing one or more 
complications, regardless of their HbA1c. Results of longer longitudinal follow up 
of the patients and future information about the course of complication devel-
opment in a lifetime perspective of the patients should emphasize the need for 
continuous evaluation of the screening protocol.
In conclusion, in 2007, the EDDDY-S study was designed with the aim to improve 
risk stratification in children and adolescents with type 1 diabetes. Tests for the 
detection of risk factors, surrogate markers and early signs of complications were 
studied for the underexposed complication fields in pediatrics: subclinical DPN, 
macrovascular complications and a surrogate marker for micro- and macrovas-
cular complications (SAF). In 2018, after the EDDDY-S study and a review of the 
current literature, we have to conclude that neither we, nor others have yet suc-
ceeded in developing screening tests that could become internationally adapted 
appropriate screening tests in the nearby future. 
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However, based on the EDDDY-S study and the review of current literature, we 
propose that the following set of promising tests for these fields of complications 
are worthwhile studying in the near future and should be added to the current 
tests in the ISPAD consensus guideline (13)(Figure 3B): 
• corneal nerve fiber density (CNFD) and corneal nerve fiber branch density 
(CNFBD) by corneal confocal microscopy (parameter category C)
• vibration perception threshold (VPT) by Biothesiometer/ Vibratory Sensory 
Analyser (parameter category B)
• stimulus intensities of the peroneal nerve by CMAP scan (parameter  
category C)
• carotid intima media thickness (cIMT) by ultrasound (parameter category B)
• pulse pressure by Dinamab (parameter category C)
• pulse-wave velocity by the SphygmoCor-Vx device (parameter category C)
• frequent lipid measurement; low-density lipoprotein cholesterol (LDL-C), 
high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), non-
HDL cholesterol (non HDL-C), triglycerides (TG) (parameter category B) 
and apolipoprotein B (apo B) (parameter category C)
• skin autofluorescence (SAF) by AGE-reader (parameter category C)
By proposing this diagnostic and research screening protocol, we think we took a 
step towards the ultimate aim of this thesis: appropriate early risk stratification in 
children and adolescents with type 1 diabetes. This may in time result in tailored 
screening and treatment, in turn, leading to an improved care process, increased 
health and quality of life and reduced long term health care costs.
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Figure 3A: ISPAD Clinical Practice Consensus Guidelines 2014. Microvascular and macrovascular compli-
cations in children and adolescents. Pediatr Diabetes. 2014;15 Suppl 20:257-69.
Three monthly: HbA1c, BMI
Neurological examination: history taking and physical exa-
mination. When to commence screening is unclear.
Fundal photography or mydriatic ophthalmoscopy from the age of
 10 years (or earlier in case of onset of puberty before the age of 10) 
onwards with 2 to 5 years of diabetes duration
Lipid profile: LDL-C, HDL-C, triglycerides after the age 
of 10 years.
Blood pressure annually 
AER/ACR or first morning albumin concentration from the age of
 10 years (or earlier in case of onset of puberty before the age of 10) 
onwards with 2 to 5 years of diabetes duration 
0 1 2 3 4 5
years
diagnosis:
type 1 diabetes
 Figure 3B: Proposed screening protocol including tests which are currently still in the research setting
0
diagnosis:
type 1 diabetes 1 2
Skin autofluorescence (SAF) measurement by AGE-reader
3 4
Corneal confocal microscopy
Vibration perception threshold 
by Biothesiometer/Vibratory Sensory Analyser
Carotid intima media thickness 
Pulse pressure 
Lipid profile PLUS apolipoprotein B and 
non-HDL-C 
 Pulse wave velocity
years
Stimulus intensities by CMAP scan 
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Figure 3A: 
 
 Neurological examination: history taking and physical examination.  
        When to commence screening is unclear. 
     Lipid profile: LDL-C, HDL-C, triglycerides after the age of 10 years. 
  AER/ACR or first morning albumin concentration from the age of 10 years (or earlier in case  
 of onset of puberty before the age of 10) onwards with 2 to 5 years of diabetes duration 
  Fundal photography or mydriatic ophthalmoscopy  from the age of 10 years (or earlier in  
 case  of onset of puberty before the age of 10) onwards with 2 to 5 years of diabetes  
 duration  
    Blood pressure annually  
    Three monthly: HbA1c, BMI 
 
Figure 3B: 
 
 Lipid profile PLUS apolipoprotein B and non-HDL-C 
 Pulse wave velocity 
 Carotid intima media thickness 
 Pulse pressure 
 Stimulus intensities by CMAP scan 
 Vibration perception threshold  by Biothesiometer/Vibratory Sensory Analyser 
 Corneal confocal microscopy 
 Skin autofluorescence (SAF) measurement by AGE-reader
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Chapter 9
Summary / Nederlandse samenvatting 
Summary
Chapter 1
In Chapter 1, we provide a short overview of type 1 diabetes and its complications. 
A considerable number of patients with type 1 diabetes still develops micro- and 
macrovascular complications despite having good glycaemic control (high HbA1c 
is the main risk factor for complications). We stress that early risk stratification, 
which was the aim of the Early Detection of Diabetes Damage in Youth and 
Search for early prevention (EDDDY-S) study presented in this thesis, will be an 
important step towards improvement of this burdensome course of the disease. 
A selection of diabetes-related complication fields (microvascular complication 
diabetic peripheral neuropathy, macrovascular complications and measurement 
of the surrogate marker advanced glycation end products [AGEs]) was made with 
the aim to cover a number of scientific gaps existing at the time the EDDDY-S 
study was conducted including the most relevant fields of complications. After 
a review of what was known about these fields, chapter 1 concludes with the 
rationale for the EDDDY-S study and the research questions. Appendix 1 provides 
a more extensive review about these fields and about the other complications in 
type 1 diabetes (that were not studied in this thesis).
Chapter 2
In Chapter 2, the usability of the compound muscle action potential (CMAP) 
scan was assessed in different groups of children and adolescents with type 1 
diabetes. The CMAP scan provides a visual and quantitative impression of the 
build-up of a muscle in terms of motor unit size and motor unit number. A pilot 
study was conducted in children and adolescents with type 1 diabetes (‘well-con-
trolled’ versus ‘poorly controlled’), adult patients with type 1 diabetes and clinical 
neuropathy, and age matched healthy controls. Significantly increased stimulus 
intensities (SIs), reflecting reduced axonal excitability, were found in both young 
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patient groups compared with their controls. We postulated the reduced axonal 
excitability to be an (early) marker of subclinical diabetic peripheral neuropathy 
(DPN). Alternatively, it could be a stand-alone finding, not necessarily indicating 
that these patients will develop DPN earlier, but being an indicator of hetero-
geneity in patients with type 1 diabetes. Despite the lack of reference tests for 
subclinical DPN and the limited number of patients, we do think that the CMAP 
scan is a promising test.
Chapter 3
In Chapter 3, we examined the diagnostic value of nerve conduction velocity 
(NCV) and the sensory nerve action potential (SNAP) amplitude of two sen-
sory nerves in detecting subclinical DPN in children and adolescents with type 
1 diabetes. In this cross-sectional pilot study, NCV and SNAP amplitude of 
the superficial peroneal nerve and the sural nerve were tested in children and 
adolescents with type 1 diabetes without clinical DPN. The group was divided 
in a group with short diabetes duration and appropriate glycaemic control and 
a group with relatively long diabetes duration, poor glycaemic control and/or 
presence of microvascular complications. The different groups were considered 
to represent absence and presence of subclinical DPN, respectively. Patients 
were compared with healthy, age-matched peers and adult patients with type 1 
diabetes and clinical DPN. NCV differed neither between the two young patient 
groups nor between patient groups and their matched controls. SNAP amplitude 
was found to be lower in the young patients considered to have subclinical DPN 
compared with their controls and the other young patient group. NCV could not 
be measured in the adult patients; SNAP amplitude could only be measured in 
a few of the adult patients. Therefore, it was not possible to compare the out-
come of NCV and SNAP amplitude measurements between the young patient 
groups and the adult patient group with cinical DPN. We concluded that NCV 
is not useful in detecting subclinical DPN in children and adolescents with type 
1 diabetes. Despite differences in SNAP amplitude between groups, regression 
analysis showed acceptable sensitivity but low specificity and accuracy, indicat-
ing that the diagnostic value of the SNAP amplitude in detecting subclinical DPN 
is limited as well. Despite the small sample size and the absence of an appropriate 
reference test in this study, we think that the diagnostic value of NCV and/or 
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SNAP of sensory nerves in detecting subclinical DPN in children and adolescents 
is currently limited. Consequently we recommend performing studies that inves-
tigate the test characteristics of methods other than measurement of NCV and 
SNAP of sensory nerves. 
Chapter 4
In Chapter 4, we summarized our findings of Chapters 2 and 3 in response to a 
paper of Professor Malik in Diabetes, stating that screening for DPN by history 
taking, physical examination and electrophysiologic tests only assesses large 
myelinated nerve fiber function. This function is assumed to deteriorate late in 
the disease course of DPN. As smaller nerve fibers are thought to deteriorate 
earlier in the disease course of DPN, he advocates using screening tests that 
focus on the smaller nerve fibers, such as corneal confocal microscopy (CCM) 
or intra-epidermal nerve fiber density in skin biopsies. Professor Malik’s sugges-
tions were supported by two of our pilot studies (Chapter 2 and 3). The validity 
of assessing subclinical DPN was found to be low when measuring large myelin-
ated sensory and motor nerve function using NCV and SNAP of the superficial 
peroneal and sural nerve and maximum CMAP amplitude of the peroneal nerve. 
Professor Malik stressed the need for more (and other) tests for detecting sub-
clinical DPN. We proposed the observed decreased axonal excitability by means 
of CMAP scan as promising technique for future study. 
Chapter 5
In Chapter 5, intima media thickness of the common carotid artery (cIMT) was 
studied in children and adolescents with type 1 diabetes and healthy controls. 
Previous studies suggested that cIMT is relevant as surrogate marker for mac-
rovascular disease in type 1 diabetes in adulthood, but the use in childhood and 
adolescence is still being debated. In addition, we studied the impact of the risk 
factors on cIMT by regression analyses: gender, socio-economic status, ethnicity, 
and current and historical body mass index, blood pressure, HbA1c, high-den-
sity lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol 
(LDL-C). We found that mean cIMT was increased in children and adoles-
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cents with type 1 diabetes, compared with healthy controls, as was the median 
age-specific cIMT. Notably, median cIMT was equally greater across all age cat-
egories. The contribution of traditional macrovascular risk factors for increased 
cIMT was limited. Both findings suggest that considerable heterogeneity exists 
between patients. If so, there may be a  subset of children and adolescents with 
type 1 diabetes that is prone to develop macrovascular complications, possibly 
already at a very young age. More research on variables allowing identification of 
these high risk patients is needed.  
Chapter 6
Chapter 6, assesses the prevalence of European children and adolescents with 
type 1 diabetes that lose their track of lipids, i.e. change from low-risk lipid levels 
into borderline-high-risk/high-risk lipid levels or from borderline-high-risk to 
high-risk levels. In addition, we studied if this ‘losing track of lipids’ could be 
predicted by a prognostic index including age, gender, HbA1c, BMI, ethnicity and 
diabetes duration. From a lifetime perspective, early identification of the high 
risk patients would provide an opportunity to timely intervene and modify their 
prognosis. Approximately 30% to 40% percent of patients lost track of lipids with 
one or more of the lipids screened at the next lipid measurement. Five to 10% 
percent of the patients lost track of LDL-C and HDL-C within a 2-year screening 
interval, whereas 25-30% did so for the other parameters. The prognostic index 
in its current form was only moderately helpful in identifying patients that lost 
track of lipids on the short term. This may be due to the rather well-regulated 
(in terms of HbA1c) study population, with a small proportion of patients having 
a BMI indicating overweight or obesity, and the absence of data on alternative 
explanatory variables (e.g. smoking and socio-economic status [SES]). We pro-
pose to initiate a longitudinal study measuring the abovementioned lipids every 
two years, including parameters related to atherogenicity (e.g. apolipoprotein B), 
puberty, non-alcoholic fatty liver disease and smoking. 
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Chapter 7
In Chapter 7, skin autofluorescence (SAF), a surrogate marker for both micro-
vascular and macrovascular complications in adults with type 1 diabetes, was 
evaluated in children and adolescents with type 1 diabetes. SAF reflects ad-
vanced glycation end products (AGEs) in the long-lived protein collagen. AGEs 
are assumed to accumulate in both the collagen of the skin and in components 
like fibrinogen and myelin. In this cross-sectional study, SAF in children and 
adolescents with type 1 diabetes was compared with healthy controls across age 
categories. Associations with current and historical HbA1c, age, and duration 
of diabetes were evaluated in the patient group. In accordance with previous 
studies, SAF was elevated in patients with type 1 diabetes. Notably, in patients 
with type 1 diabetes, SAF was equally elevated across all age categories, but only 
weakly associated with duration of diabetes and age, and not correlated with the 
current and historical HbA1c values. Surprisingly, it was even found to be elevated 
in a subgroup of patients with an HbA1c ≤ 7.5% (58 mmol/mol), considered to be 
a ‘HbA1c-within-target’. Although these findings were unexpected, the presence 
of a subgroup with elevated SAF despite having appropriate glycaemic control, 
suggests that measurement of SAF may have added value in risk-assessments for 
future diabetes related complications. The results also suggests that glycaemic 
control may not be the main or exclusive contributor in the development of com-
plications in all patients. Consequently, determinants other than age, duration of 
diabetes and HbA1c, and/or heterogeneity within the patient group are likely to 
be involved. 
Chapter 8
Chapter 8 briefly looks back at the general introduction and research ques-
tions, followed by a  summary of the EDDDY-S study results. Then the two main 
general findings of the EDDDY-S study are presented: 1) in at least a subgroup of 
children and adolescents with type 1 diabetes in the EDDDY-S study glycaemic 
control did not or only moderately contribute to development of abnormal values 
of surrogate markers and/or early signs of micro- and macrovascular complica-
tions; 2) the EDDDY-S study showed already abnormality in surrogate markers 
and early signs of complications in a considerable number of the children and 
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adolescents with type 1 diabetes. Next, results are put in context of complica-
tions-related literature reported from 2007 to 2018 (while the EDDDY-S study 
was executed). For more extensive information about these fields and new sci-
entific insights in the other complications of type 1 diabetes the reader is referred 
to Appendix 2. Finally, chapter 8 elaborates on EDDDY-S study related method-
ological considerations, integration of the EDDDY-S study results with the new 
scientific insights of 2007-2018 and future study implications. 
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Hoofdstuk 1
In hoofdstuk 1 wordt een kort overzicht gegeven over het ziektebeeld type 1 
diabetes en de complicaties die hierbij kunnen optreden. Het beschrijft dat een 
aanzienlijk gedeelte van de patiënten micro- en macrovasculaire complicaties 
ontwikkelt en dat dit gebeurt ondanks een goede regulatie van de belangrijkste 
risicofactor; slechte glucosecontrole (ofwel een hoog HbA1c). In hoofdstuk 1 
benadrukken we dat vroege risicostratificatie uiteindelijk moet leiden tot een 
verbetering van deze sombere prognose. Het onderzoek dat wordt gepresenteerd 
in dit proefschrift (EDDDY-S [Early Detection of Diabetes Damage in Youth and 
Search for early prevention] studie) heeft als doel deze risicostratificatie te ver-
beteren. Met focus op de onderbelichte onderdelen binnen het veld van compli-
caties beslaat de EDDDY-S studie maar een deel van het gehele veld van com-
plicaties. Hoofdstuk 1 geeft een overzicht van wat er bekend was in 2007 over de 
onderzochte complicatievelden; de microvasculaire complicatie diabetesgerela-
teerde perifere neuropathie (DPN), macrovasculaire complicaties en meting van 
de surrogaatmarker ‘advanced glycation end products’ (AGEs). Hoofdstuk 1 ein-
digt met de rationale van de EDDDY-S studie en de onderzoeksvragen. Appendix 
1 bevat een uitgebreider overzicht van de kennis in 2007 omtrent de complicati-
evelden die reeds besproken werden in hoofdstuk 1 alsmede een overzicht van 
kennis in 2007 omtrent de andere complicaties in type 1 diabetes. 
Hoofdstuk 2
In hoofdstuk 2 wordt het gebruik van de ‘compound muscle action potential’ 
(CMAP) scan in verschillende groepen kinderen en adolescenten met type 1 
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diabetes onderzocht. De CMAP scan geeft visueel en quantitatief de opbouw 
van een spier weer, waarbij gekeken wordt naar motor unit grootte en aantal. 
Er werd een pilot studie opgezet met daarin kinderen en adolescenten met 
type 1 diabetes (goed gereguleerde patiënten vs slecht gereguleerde patiënten) 
en volwassen patiënten met type 1 diabetes en klinisch neuropathie. Voor alle 
patiëntengroepen waren er leeftijd-gematchte gezonde controles. Er werd een 
significant verschil gemeten in de CMAP parameter stimulusintensiteit waarmee 
een verminderde axonale prikkelbaarheid werd aangetoond in de jonge patiënten 
met type 1 diabetes in vergelijking tot de gezonde controlegroep. We hypothe-
tiseren dat deze verminderde axonale prikkelbaarheid een (vroeg) teken is van 
subklinische DPN. Een alternatief voor deze hypothese is dat het een op zichzelf 
staande bevinding is, waarbij de bevinding er niet op wijst dat deze patiënten per 
definitie DPN ontwikkelen en dat het wellicht meer een bevinding is die duidt 
op heterogeniteit in de groep patiënten met type 1 diabetes. We denken dat de 
CMAP scan een veelbelovende test is ondanks de afwezigheid van een referenti-
etest en een beperkt aantal patiënten in deze studie.
Hoofdstuk 3 
In hoofdstuk 3 werd de diagnostische waarde van het meten van de zenuwgeleid-
ingstijd en de SNAP (sensory nerve action potential) amplitude van 2 sensorische 
zenuwen bestudeerd met betrekking tot de detectie van subklinische DPN in 
kinderen en adolescenten met type 1 diabetes. Het betrof een cross-sectionele 
pilotstudie waarin de zenuwgeleidingstijd en de SNAP amplitude werd gemeten 
in de nervus peroneus superficialis en de nervus suralis bij kinderen en adoles-
centen met type 1 diabetes zonder klinische DPN. De patiëntengroep bestond 
uit twee groepen. De ene groep had een korte duur van de ziekte type 1 diabetes 
en goede glucoseregulatie; deze groep had een lage verdenking op subklinische 
DPN. De andere groep had een lange duur van de ziekte type 1 diabetes en 
slechte glucoseregeling en/of aanwezigheid van microvasculaire complicaties en 
had daarmee een hoge verdenking op aanwezigheid van subklinische DPN. De 
zenuwgeleidingstijd en de SNAP amplitude werden vergeleken met gezonde, 
leeftijd-gematchte controles en volwassenen met type 1 diabetes en klinische 
DPN. Er werd geen verschil gemeten in zenuwgeleidingssnelheid tussen de twee 
jonge patiëntengroepen onderling en ook niet tussen de jonge patiëntengroepen 
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en de controles. De SNAP amplitude was wel lager in de patiëntengroep die een 
hoge verdenking had op subklinische DPN wanneer deze werd vergeleken met de 
andere jonge patiëntengroep en met de gezonde controles. De zenuwgeleiding-
stijd kon niet gemeten worden in de volwassen patiënten met klinische DPN; de 
SNAP amplitude kon maar in een klein aantal van deze patiëntengroep gemeten 
worden. Hierdoor konden geen vergelijkingen plaatsvinden tussen de zenuwge-
leidingssnelheid en SNAP amplitude van de volwassenen en de jonge patiënten. 
We concludeerden dat het niet zinvol is om de zenuwgeleidingssnelheid te geb-
ruiken voor het detecteren van subklinische DPN in kinderen en adolescenten 
met type 1 diabetes. Regressieanalyses toonden aan dat de sensitiviteit voor het 
detecteren van subklinische DPN van de SNAP amplitude acceptabel was, maar 
dat de specificiteit en nauwkeurigheid laag was. Derhalve concludeerden we 
tevens dat ook de SNAP amplitude geen goede maat is voor detectie van sub-
klinische DPN in kinderen en adolescenten met type 1 diabetes. 
Wij trekken voorgaande conclusies ondanks de kleine groepsgrootte en de 
afwezigheid van een referentietest in deze studie. We adviseren onderzoek naar 
andere testen voor de detectie van subklinische DPN in deze leeftijdsgroep.
Hoofdstuk 4
Hoofdstuk 4 bevat een reactie (letter to the editor) op een manuscript van 
Professor Malik in het tijdschrift Diabetes waarin de conclusies van hoofdstuk 2 
en 3 kort zijn samengevat. Malik stelt dat het navragen van DPN-gerelateerde 
klachten, het doen van lichamelijk onderzoek en het verrichten van electrofy-
siologische studies (zoals de zenuwgeleidingssnelheid en de SNAP amplitude) 
schade detecteren aan de grote, gemyeliniseerde zenuwvezels waar de gedachte 
is dat kleine, niet- gemyeliniseerde zenuwvezels eerder beschadigd raken in het 
traject van DPN. Hij pleit daarom voor testen die focussen op het detecteren van 
schade aan deze kleine, niet-gemyeliniseerde zenuwvezels en noemt als mogeli-
jke testen de ‘corneal confocal microscopy’ en de intra-epidermale zenuwve-
zeldichtheid gemeten in huidbiopten. We hebben gereageerd op zijn publicatie 
omdat de bevindingen van onze twee pilotstudies, beschreven in hoofdstuk 2 
en 3, zijn idee over de volgorde van schade ondersteunen. Immers, de validiteit 
van de testen voor subklinische DPN, die de functie meten van de grote gemy-
eliniseerde zenuwvezels met behulp van de zenuwgeleidingssnelheid, SNAP 
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amplitude (sensorische zenuwen nervus peroneus superficialis en de nervus 
suralis) en de maximale CMAP amplitude (motore zenuw nervus peroneus) was 
laag. Professor Malik benadrukt de noodzaak tot meer (en andere) testen dan de 
bestaande testen om subklinische DPN beter te kunnen detecteren. Wij onder-
schrijven dit en hebben de geobserveerde verminderde axonale prikkelbaarheid, 
gemeten door middel van de CMAP scan, genoemd als veelbelovende test die 
nadere studie behoeft. 
Hoofdstuk 5
In hoofdstuk 5 wordt de intima-media dikte van de gemeenschappelijke arterie 
carotis (cIMT) gemeten in kinderen en adolescenten met type 1 diabetes. Eerd-
ere studies hadden in volwassenen met type 1 diabetes aangetoond dat de cIMT 
als surrogaat marker van macrovasculaire schade kan dienen. Of je de cIMT op 
die manier ook zou kunnen gebruiken in kinderen en adolescenten met type 1 
diabetes werd in 2007 nog bediscussieërd. We hebben de cIMT in deze patiën-
tengroep gemeten en vergeleken met gezonde controles. Daarnaast hebben we 
regressieanalyses verricht om de impact van de volgende factoren op cIMT te 
beoordelen in de patiënten: geslacht, socio-economische status (SES), ethnic-
iteit, BMI, HbA1c, bloeddruk, HDL-C (high-density lipoprotein cholesterol) en 
LDL-C (low-density lipoprotein cholesterol) ten tijde van de cIMT meting en 
BMI, HbA1c, bloeddruk, HDL-C en LDL-C uit het verleden. We vonden dat de 
cIMT verhoogd is in kinderen en adolescenten met type 1 diabetes vergeleken 
met gezonde controles. Dit is ook het geval als je de cIMT per leeftijdscategorie 
bekijkt. Hierbij valt tevens op dat a) het verschil in cIMT tussen patiënten en con-
troles steeds ongeveer even veel is en b) de impact van de onderzochte factoren 
op de (verhoging) van de cIMT maar matig is. We vermoeden dat deze bevindin-
gen een gevolg zijn van heterogeniteit in de patiëntengroep. Als dat inderdaad 
zo is, zou dit ook kunnen betekenen dat een subgroep van patiënten gedoemd 
is om macrovasculaire complicaties te krijgen en dat dit zelfs al kan plaatsvinden 
op een relatief jonge leeftijd. Meer onderzoek om deze subset van hoog risico 
patiënten te detecteren is nodig.
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Hoofdstuk 6
In hoofdstuk 6 hebben we bekeken hoeveel kinderen en adolescenten met type 
1 diabetes kampen met het verschijnsel ‘lose track of lipids’(gedefinieërd als de 
verandering van een laag-risico lipidewaarde naar een borderline-hoog-risico / 
hoog-risico lipidewaarde of van een borderline-hoog-risico lipidewaarde naar 
een hoog-risico lipidewaarde). We hebben tevens bekeken of een prognostische 
index bestaande uit de factoren leeftijd, geslacht, HbA1c, BMI, ethniciteit en 
duur van de ziekte diabetes in staat is om het verschijnsel ‘losing track of lipids’ 
te voorspellen. Vanuit een levensloop perspectief is het belangrijk om patiënten 
met een hoog risico voor ‘losing track of lipids’ te identificeren zodat het mogelijk 
is om op tijd te interveniëren en daarmee de prognose te verbeteren. Ongeveer 
30-40% van de patiënten ‘lost track’ van 1 of meerdere van de bestudeerde 
lipiden, wanneer er naar de 2e lipidemeting gekeken werd. Vijf tot tien procent 
van de patiënten deed dit met hun ‘low-density lipoprotein cholesterol’ (LDL-C) 
of ‘high-density lipoprotein cholesterol’ (HDL-C) binnen het 2-jaar screenings 
interval. Ongeveer 25-30% deed dit met een van de andere bestudeerde lipiden 
(totaal cholesterol, triglyceride, non-HDL-C). De prognostische index bleek 
beperkt in staat te zijn tot het voorspellen van welke patiënten ‘lose track of 
lipids’. Mogelijk heeft hierbij meegespeeld dat een groot deel van de studiegroep 
een goed HbA1c had en dat er maar een klein percentage van de studiegroep een 
BMI had in de overgewicht- of obesitascategorie. Wellicht speelt het niet includ-
eren van gegevens over andere mogelijke determinanten zoals rookgedrag en so-
cio-economische status ook een rol. We stellen een nieuwe longitudinale studie 
voor waarin de bestudeerde lipiden iedere 2 jaar gemeten worden, aangevuld met 
gegevens over atherogeniciteit in de vorm van apolipoprotein B en gegevens over 
puberteit, ‘non-alcoholic fatty liver disease’ en roken. 
Hoofdstuk 7
Hoofdstuk 7 evalueert de autofluorescentie van de huid (SAF) in kinderen en ad-
olescenten met type 1 diabetes. SAF is een surrogaatmarker voor zowel micro- als 
macrovasculaire complicaties in volwassenen met type 1 diabetes. Het geeft de 
hoeveelheid advanced glycation end products (AGEs) weer van collageen, een 
eiwit met een lange halfwaarde tijd. AGEs stapelen zich op in het collageen van 
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de huid en in componenten zoals fibrinogeen en myeline. SAF werd gemeten bij 
kinderen en adolescenten met type 1 diabetes en vergeleken met SAF gemeten in 
gezonde controles in verschillende leeftijdscategorieën in deze cross-sectionele 
studie. In de patiëntengroep werd er tevens gekeken naar associaties tussen SAF 
en HbA1c ten tijde van de SAF meting en HbA1c uit het verleden en associaties 
tussen SAF en de determinanten leeftijd en duur van de ziekte diabetes.  
Net als eerdere studies vonden wij dat SAF was verhoogd in patiënten met type 1 
diabetes vergeleken met de gezonde controles. Opmerkelijk was de bevinding dat 
SAF gelijkmatig was verhoogd in patiënten van verschillende leeftijdscategorieën. 
De associatie met de duur van de ziekte diabetes en de leeftijd was matig en er 
werd geen associatie gevonden met SAF en actueel HbA1c of HbA1c waardes uit 
het verleden. Tenslotte viel op dat er een klein groepje patiënten was dat een ver-
hoogde SAF had ondanks een goed HbAc (HbA1c ≤ 7.5% [58 mmol/mol]). Deze 
bevinding alsmede de bevinding dat er geen associatie werd gevonden tussen 
SAF en Hb1Ac uit het verleden hadden we niet verwacht. Desalniettemin leidt de 
aanwezigheid van een subgroep patiënten met een verhoogd SAF ondanks goed 
HbA1c tot de conclusie dat SAF meting mogelijk toegevoegde waarde heeft in 
de risico-inschatting voor toekomstige diabetesgerelateerde complicaties. Deze 
studieresultaten suggereren daarnaast dat niet slechts of vooral glucosecontrole 
bijdraagt aan de ontwikkeling van complicaties in alle patiënten. Andere factoren 
dan leeftijd, duur van de ziekte diabetes en HbA1c en/of heterogeniteit van pa-
tiënten spelen hierbij mogelijk een rol. 
Hoofdstuk 8
Hoofdstuk 8 kijkt terug op de introductie van het proefschrift en de onder-
zoeksvragen, gevolgd door een samenvatting van de resultaten in de EDDDY-S 
studie. Hierna worden de twee overkoepelende bevindingen van de EDDDY-S 
studie gepresenteerd: 1) in tenminste een subgroep van de kinderen en adoles-
centen met type 1 diabetes uit de EDDDY-S studie droeg glucosecontrole niet 
of maar matig bij aan de ontwikkeling van abnormale waardes van de surrogaat-
markers en/of vroege tekenen van micro- en macrovasculaire complicaties; 2) 
in een vrij groot aantal van de kinderen en adolescenten met type 1 diabetes in 
de EDDDY-S studie waren afwijkende surrogaatmarkers of vroege tekenen van 
complicaties al aantoonbaar. Hoofdstuk 8 wordt vervolgd met een integratie van 
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de resultaten van de EDDDY-S studie en complicatiegerelateerde literatuur uit 
2007-2018 (periode waarin de EDDDY-S studie werd uitgevoerd). Voor meer 
uitgebreide informatie omtrent deze onderwerpen en nieuwe wetenschappelijke 
inzichten in de andere complicatievelden van type 1 diabetes wordt verwezen 
naar appendix 2. Tenslotte bespreekt hoofdstuk 8 methodologische kwesties die 
de EDDDY-S studie aangaan. Hoofdstuk 8 eindigt met implicaties van de bevin-
dingen voor toekomstige studies.
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Appendix 1
Here we summarize the available data in 2007 on A) risk factors other than 
glycaemic control for development and/or progression of micro- and macrovas-
cular complications, B) relevant and promising tests for detection of early signs of 
these micro- and macrovascular complications.
Microvascular complications
Nephropathy
Approximately 30% of the patients with type 1 diabetes develops diabetic ne-
phropathy and about 10% develops end stage renal disease after 30 years of 
diagnosis (1-4). In 2007, screening for nephropathy was performed by the annual 
measurement of urinary albumin concentration or urinary albumin-to-creati-
nine-ratio in spot urine from the age of 10 onwards or earlier in case of start of 
puberty before the age of 10 if duration of diabetes was > 2-5 years (5, 6). In 
adults, soluble intercellular adhesion molecule-1 (s-ICAM), an inflammatory 
related adhesion molecule, and increased levels of soluble CD40 (sCD40) ligand 
were shown to precede the development and worsening of microalbuminuria (7, 
8). 
Neuropathy
Clinical neuropathy (defined as clinical diabetic polyneuropathy (DPN) and/or 
autonomic neuropathy) develops in about 20% of the adult patients with type 1 
diabetes (3, 4, 9, 10), whereas subclinical neuropathy (defined as abnormal nerve 
conduction velocity and/or autonomic neuropathy) was found in about 30 % (9). 
In adolescents with type 1 diabetes, clinical and subclinical neuropathy is already 
prevalent in a considerable part of the patients (11, 12). Its prevalence has been 
shown to increase whereas the prevalence of retinopathy and microalbuminuria 
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Appendix 1 
Here we summarize the available data in 2007 on A) risk factors other than 
glycaemic control for development and/or progression of micro- and macrovas-
cular complications, B) relevant and promising tests for detection of early signs of 
these micro- and macrovascular complications.
Microvascular complications
Nephropathy 
Approximately 30% of the patients with type 1 diabetes develops diabetic ne-
phropathy and about 10% develops end stage renal disease after 30 years of 
diagnosis (1-4). In 2007, screening for nephropathy was performed by the annual 
measurement of urinary albumin concentration or urinary albumin-to-creati-
nine-ratio in spot urine from the age of 11 years onwards with 2 years of diabetes 
duration and from the age of 9 years with 5 years of diabetes duration (5, 6). In 
adults, soluble intercellular adhesion molecule-1 (s-ICAM), an inflammatory 
related adhesion molecule, and increased levels of soluble CD40 (sCD40) ligand 
were shown to precede the development and worsening of microalbuminuria (7, 
8). 
Neuropathy
Clinical neuropathy (defined as clinical diabetic polyneuropathy (DPN) and/or 
autonomic neuropathy) develops in about 20% of the adult patients with type 1 
diabetes (3, 4, 9, 10), whereas subclinical neuropathy (defined as abnormal nerve 
conduction velocity and/or autonomic neuropathy) was found in about 30 % (9). 
In adolescents with type 1 diabetes, clinical and subclinical neuropathy is already 
prevalent in a considerable part of the patients (11, 12). Its prevalence has been 
shown to increase whereas the prevalence of retinopathy and microalbuminuria 
declined over the years (11). In addition to DPN, autonomic neuropathy is  
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assumed to develop early in the disease process as well (13).
Table 1: Types of diabetic neuropathy (14-16) 
 
Sensorimotor diabetic polyneuropathy
Dysfunction of the peripheral sensorimotor nerves
Focal neuropathy
Mononeuropathy, cranial neuropathy
Autonomic diabetic neuropathy
Cardiovascular, gastro-intestinal, bladder, erectile, and sudomotor dysfunction
Diabetic neuropathy is regarded to be a microvascular complication, related to 
damage of endothelial cells in vessels supplying peripheral nerves and ganglia. 
The pathophysiology is thought to be multifactorial (16, 17). Factors such as 
advanced glycation end products (AGEs), oxidative stress, glucotoxicity, certain 
genetic polymorphisms, vascular cell adhesion molecules, neurotrophine growth 
factors and inflammatory changes are reasoned to be involved in damaging not 
only the endothelial cells, but also other structures such as Schwann cells and 
neurofilaments (17, 18). As implicated by the different forms of neuropathy, large- 
and small-diameter, myelinated and unmyelinated, motor, sensory and autonom-
ic nerve fibers can be affected (16, 18). The order of deterioration of these various 
nerve fibers is still an ongoing debate. In general it is assumed that sensory nerve 
fibers deteriorate earlier in the disease course of DPN than motor nerve fibers do 
(17, 19). Moreover, some postulate small myelinated and unmyelinated (senso-
ry) nerve fibers to precede deterioration of the myelinated (sensory and motor) 
nerve fibers (12, 20, 21). 
The screening guideline for diabetic neuropathy includes history taking, mainly 
covering complaints related to DPN (6). The more objective tests for (sub)clinical 
DPN in this guideline consist of examination of autonomic nerve function, testing 
the vibration perception threshold (VPT) (large myelinated nerve fibers test), 
testing the thermal perception thresholds (small myelinated and unmyelinated 
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nerve fiber test) and performance of NCV (large myelinated nerve fiber test). 
The guideline includes testing of large sensory and motor myelinated nerve fibers 
but underexposes the possible order of small nerve fiber deterioration preceding 
the large ones. 
By 2007, more tests became available for earlier detection of (subclinical) DPN 
with more attention for small nerve fibers and were studied in addition to tests 
focussing on early detection of large nerve fiber damage.
These tests included examining the density of the smaller unmyelinated and 
myelinated nerve fibers by fascicular sural nerve biopsy (21, 22), examining the in-
tra-epidermal nerve fiber density in skin biopsy (23, 24), looking at corneal nerve 
fiber density by corneal confocal microscopy (24), measuring the amplitude of 
motor peripheral nerves (20, 25, 26) and examining electrophysiological features 
of the dorsal sural nerve (27). In addition to various tests assessing small myelin-
ated and unmyelinated nerve fibers and large myelinated nerve fibers, attention 
was also paid to the detection of early signs of autonomic neuropathy. Testing 
of sudomotor function using the Neuropad (23, 28) and the horizontal pupillary 
diameter (29) were described to be feasible as novel tests. 
Retinopathy
Retinopathy and  laser-treated retinopathy develops in approximately 10-50% 
and 20% respectively of the patients with type 1 diabetes (3, 4, 30, 31). In 2007, 
annual screening for diabetic retinopathy was advised to be performed by 7-field 
stereoscopic fundus photography, fluorescein angiography, indirect ophthal-
moscopy or monochromatic single-field photography from the age of 11 years 
onwards in case of ≥ 2 years diabetes duration and from 9 years onwards in case 
of ≥ 5 years duration (6, 32). Tumor necrosis factor alfa (TNFalfa) serum levels 
(33, 34) and retinal arteriolar, venular diameter and the arteriolar/venular ratio 
by retinal photography (assessed with a computer-assisted programme) were 
suggested to predict development and progression of retinopathy (31, 35).
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Macrovascular complications
Mortality due to the macrovascular complications ischaemic heart disease and 
cerebrovascular disease in childhood-onset type 1 diabetes is substantially in-
creased in type 1 diabetes compared with the general population (36-38). 
The ISPAD guideline (6) recommends screening every year for the risk factor 
hypertension and every 5 years for the risk factor dyslipidemia from the age of 
12 years onwards. It also presents target levels regarding body mass index (BMI), 
smoking behaviour and other known risk factors for macrovascular disease such 
as HbA1c. These recommendations lack assessment of any surrogate marker for 
macrovascular disease. 
By 2007, measurement of carotid intima media thickness, endothelial dysfunc-
tion and arterial stiffness, were already suggested to be surrogate markers for 
macrovascular disease.  
Atherosclerosis leads to premature cardiovascular disease (39) and has been 
shown to develop, among others, in the carotid intima (40). Therefore, mea-
surement of the carotid intima media thickness (cIMT) was considered to be an 
appropriate surrogate marker of subclinical atherosclerosis. Indeed, increased 
cIMT was shown to associate with coronary heart disease in adults without type 
1 diabetes (39, 41). In the Pathobiological Determinants of Atherosclerosis in 
Youth (PDAY) study (42) it was shown that risk factors associated with extended 
atherosclerosis (notably hyperglycaemia) coincide with risk factors for increased 
cIMT (43, 44) and are able to predict future cIMT increases (45). Moreover, 
increased cIMT has been found in adult patients with type 1 diabetes (46). In 
this research setting it was also found that atherosclerosis was already present in 
patients aged 15-34 years who died of external causes. Most, but not all, studies 
found an increased cIMT in the children and adolescents with type 1 diabetes as 
compared with healthy controls (47-51).
Endothelial dysfunction is associated with diminished nitric oxide levels and al-
tered expression of cellular adhesion molecules which in turn result in enhanced 
leucocyte adhesion to the endothelium surface, decreased vasodilatation and 
increased thrombotic state. As a consequence of this disrupted vascular homeo-
stasis, cardiovascular disease occurs (52-54). Endothelium dysfunction is reflect-
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ed by: an impaired vasodilatory response of the coronary arteries to acetylcholine 
(examined by quantitative angiography); impaired flow-mediated dilatation 
(FMD) of the brachial artery using high-resolution ultrasound; and altered in-
tra-arterial forearm blood flow responses to substances such as methacholine by 
means of using strain gauge plethysmography (52-56). These parameters have 
been found to be associated with type 1 diabetes, cardiovascular risk factors and 
cardiovascular disease itself (53-58).
Arterial stiffness is a consequence of changes of the predominant components of 
the intracellular and extracellular matrix of the vascular wall: collagen and elastin. 
These changes are due to factors such as elevated luminal pressure, inflamma-
tion, altered metalloproteinases and the amount of advanced glycation end prod-
ucts, and result in impaired cross-links and an altered proportion of functioning 
collagen and elastin in the vascular wall (59, 60). Increased vascular stiffness has 
been shown to associate with cardiovascular disease (61-63), the cardiovascular 
risk factor hypertension (64) and type 1 diabetes (61, 64, 65). It can be measured 
by various methods, e.g. calculating the augmentation index from radial tonome-
try values (66), calculating pulse pressure from systolic and diastolic blood pres-
sure measured by a random sphygmomanometer (61), and determine pulse-wave 
velocity by an automatic device (64). 
In addition to these surrogate markers for macrovascular complications, atten-
tion has increased for improving macrovascular risk stratification by looking into 
the atherogenicity of the lipid profile and inflammatory markers. The lipid profile 
got extended with the determination of apolipoprotein B (apoB) levels (67, 68), 
apoB/apolipoprotein A-I (apo A-I) levels, and low-density lipoprotein cholester-
ol (LDL-C) density markers (67) and inflammatory markers such as C-Reactive 
protein (CRP) (69, 70). Finally, two lipid studies in children and adolescents with 
type 1 diabetes in respectively 2007 and 2008 showed the lipid level to change 
from low-risk into borderline-high-risk or high-risk lipids levels or from border-
line-high-risk into high-risk lipid levels (‘lose track of lipids’) in a considerable 
number of patients within a shorter interval of time than the suggested 5 year 
interval of the guideline (6, 71, 72). This warrants earlier detection of and conse-
quently intervention for the risk factor dyslipidemia.
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Additional risk factors and surrogate markers 
Advanced glycation end products (AGEs) as surrogate marker for complications 
AGEs are products of reactive oxygen species and non-enzymatic reactions be-
tween sugars and amino groups of proteins (‘Maillard reaction’) (73, 74). Its pro-
duction is enhanced in patients with higher glucose levels and other saccharide 
derivatives (75-77). Local accumulation of AGEs causes structural alteration of 
long-lived proteins such as collagen, fibrinogen and myelin through the formation 
of intermolecular and intramolecular cross-links (75-77). AGEs also affect the 
formation of free radicals and nitric oxide and trigger receptor dependent (e.g. 
RAGE) and receptor independent pro-inflammatory pathways (75-77). These 
processes result in, among others, increased stiffness of blood vessels, decreased 
arterial and myocardial compliance, glomerular basement membrane thickening, 
basement membrane thickening of the retinal blood vessels, reduction of LDL-C 
uptake and decreased blood flow to nerves due to micro-angiopathy (75-77). 
Associations between AGEs and micro- and macrovascular complications in type 
1 and type 2 diabetes were described in adults (76-79). Quantification of AGEs 
has been studied by: measurement of serum levels of certain AGEs (80, 81); 
measurement of collagen glycation by determining the plantar fascia thickness 
in children and adolescents (82); and skin autofluorescence (SAF) in adults only 
(79, 83).
Inflammatory markers as surrogate marker for complications
Several studies showed that the serum levels of inflammatory markers such as 
soluble tumor necrosis alfa receptor (sTNF-R), tumor necrosis alfa factor (TNF 
alfa), C-Reactive Protein (CRP) and interleukine 6 (IL-6) associate with the 
concomitant presence of (early signs) of complications (34, 69, 70, 84, 85). In 
type 1 diabetes related nephropathy, sICAM-1 and soluble CD40 levels have been 
suggested to be useful as prediction markers of vascular endothelial damage and 
thus complications (7, 8, 86). 
Insulin resistance as additional factor for the development of complications
Yip et al showed by euglycaemic hyperinsulinaemic clamp method that adult 
patients with type 1 diabetes and  microalbuminuria had a decreased glucose 
disposal rate (measure of insulin sensitivity) when compared with patients with 
normoalbuminuria (87). Orchard et al confirmed this finding by their study in 
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which they found insulin resistance, measured by an estimated glucose disposal 
rate (eGDR), to associate with coronary artery disease independent of diabetes 
duration and age in a subgroup of childhood-onset type 1 diabetes patients of the 
Pittsburgh Epidemiology of Diabetes Complication Study (88). 
Genetic susceptibility as additional risk factor for the development of complications
Only a few studies highlighted the importance of polymorphisms in genes in-
volved in the process of arterial stiffness and nephropathy in type 1 diabetes (8, 
88, 89).
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New scientific insights in the period 2007-2018 while the EDDDY-S study was 
performed.
Microvascular complications
Nephropathy
Both the approaches by the research group of Donaghue (1, 2) and by the Oxford 
Regional Prospective Study of Childhood Diabetes (3) are worthwhile to consider 
for the identification of the adolescent patients with type 1 diabetes at risk for 
developing nephropathy. The former approach used a cut-off limit of the albumin 
excretion rate (AER) lower than the 20 microgr/min recommended in the guide-
line (1, 2, 4, 5), because a previous study of Chase showed this lower cut-off limit 
to associate with future abnormal AER (5). In the latter approach ACRs (Albumin 
to Creatinin Ratio) in the highest tertile of the normal range were found to predict 
the development of microalbuminuria (3, 6). Alternative ways for the detection 
of early signs of nephropathy, were regarded to be tests such as retinal vascular 
geometry and measurement of Cystatine C. Associations between several abnor-
mal retinal vascular geometry measures and baseline abnormal ACR, short-term 
future abnormal ACR and long-term micro- and macroalbuminuria were shown 
(7-10). In a 10 year follow-up study of adults with type 1 diabetes, Premaratne et 
al. showed serum Cystatine C to be more sensitive in predicting a declining renal 
function than creatinine-based measures (11). Few studies in adolescents with 
type 1 diabetes were performed. These studies showed the same might be true 
for this age-group, but the follow up duration in the studies was only 1.5-2 years, 
addressing the need for long-term data in pediatric patients with type 1 diabetes 
(12, 13). 
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Neuropathy
In the period 2007-2018, the literature increasingly focused on small nerve fiber 
dysfunction preceding large nerve fiber dysfunction in the development of DPN. 
Additionally, more sensitive tests in both detecting large nerve fiber dysfunction 
and autonomic nerve fiber dysfunction were evaluated.
Promising tests being indicative for small nerve fiber function were developed. In 
adult patients with type 1 diabetes, corneal nerve fiber density (CNFD) and cor-
neal nerve fiber branch density (CNFBD) measured by means of corneal confo-
cal microscopy (CCM) were shown to correlate with intra-epidermal nerve fiber 
(branch) density in skin biopsies (14). Additionally, the significance of associa-
tions between several corneal nerve measurements and severity of clinical DPN 
(14-16), small nerve fiber function tests (14, 17) and the development of future 
DPN (18) was investigated and confirmed. Contradicting results were found re-
garding the benefits of corneal sensation threshold measurements by noncontact 
corneal esthesiometry (NCCE) (15, 18). 
Potentially more sensitive screening tests detecting large nerve fiber dysfunction 
were also evaluated (19). Regarding the determination of the vibration perception 
threshold (VPT), the Biothesiometer or Vibratory Sensory Analyser appeared to 
have a better diagnostic utility than the tuning fork or the Vibratron II (1, 2, 19)(20) 
in detecting subclinical DPN in children and adolescents with type 1 diabetes. 
Besides, testing the tactile function with smaller monofilaments (1 mN) than the 
thicker ones used in adult screening was evaluated and appeared promising (as 
also suggested by Vinik (21)). However, sensitivity appeared low in a study in 88 
children with type 1 diabetes (22). A follow-up study of Hyllienmark showed that 
the 9 patients (15% of the total group) having clinical DPN at young adult age had 
an impaired peroneal and median motor nerve conduction velocity and/or sural 
sensory nerve action potential at baseline (mean age at baseline 15.5 years [3.22 
SD])(23). Monlun reported hyperglycaemie to affect nerve conduction velocity 
but not sensory nerve action potential when present during neurophysiologic 
testing (24). 
Recent research regarding autonomic neuropathy paid more attention to early 
warning signs of cardiac autonomic neuropathy (CAN) and sudomotor function. 
CAN appeared to be detectable in the first years after diabetes onset by means 
of validated cardiovascular reflex tests supported by newer procedures (25). Such 
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warning signs include reduced heart rate variability during deep breath, prolon-
gation of QT interval (determined by ECG), decreased baroreflex sensitivity with 
consequent abnormal blood pressure regulation, and orthostatic hypotension 
(26). The applicability of testing the sudomotor function by the Neuropad test 
and Electrochemical skin conductance (e.g. sudoscan) was examined in several 
studies. Abnormal tests were associated with impaired small nerve fiber function 
tests and neuropathic severity (27-30), although the results were contradicting 
(27, 28, 31, 32). 
Despite the potential of these novel tests, recent studies in both adults and in 
children and adolescents, do not clarify if small nerve fiber testing alone is suffi-
cient for detecting subclinical DPN (which would be in line with the hypothesis 
that small nerve fiber dysfunction precedes large nerve fiber dysfunction (21, 33, 
34)). In adults with type 1 diabetes, Breiner showed ≥ 1 of the 4 small nerve fiber 
tests to be abnormal in 97% of the patients with clinical large nerve fiber dysfunc-
tion (defined by abnormal electrophysiologic studies and/or clinical DPN)(34). 
However, this study lacks longitudinal data on future large nerve fiber impairment 
in the patients with ≥ 1 abnormal small nerve fiber test and no clinical signs of 
large nerve fiber function at baseline. Pritchard performed a (short) longitudi-
nal study and found both baseline small and large nerve fiber dysfunction to be 
associated with clinical DPN after a mean follow up period of 47 months (+/- 3 
standard deviation) (18). In children, adolescents and young adults with type 1 di-
abetes, only cross-sectional studies were performed. These studies tested small 
nerve fiber function only or performed a combination of large- and small nerve 
fiber function tests (1, 2, 35-37). In a pilot study in adolescents with type 1 diabe-
tes (n=6) Sellers et al. did not find a difference in corneal confocal microscopy 
(CCM) measures when compared with healthy age-matched controls (37), per-
haps due to small sample size. Cho et al. tested VPTs (large nerve fiber) by means 
of Biothesiometer/ Vibratory Sensory Analyser in combination with thermal 
thresholds (small nerve fibers) by means of Thermal Threshold Tester/ Neuro-
sensory TSA-II and found subclinical DPN in 14-28% of the children and adoles-
cents with type 1 diabetes (1, 2). Regrettably, it was not specified which of the two 
performed tests were abnormal in their patient group. Weintrob and Blankenburg 
investigated large nerve fiber dysfunction and small nerve fiber dysfunction in 
type 1 diabetes in young adults and adolescents respectively (35, 36). There were 
more patients showing small nerve fiber dysfunction than patients showing large 
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nerve fiber dysfunction. However, neither study could show if patients with small 
nerve fiber dysfunction concomitantly had large nerve fiber dysfunction. More-
over, longitudinal data are lacking. 
Retinopathy
Retinal photography continues to be the predominantly performed test for 
screening for retinopathy. The DCCT/EDIC Research group re-evaluated the 
intervals of fundus photography screening schedule. Based on standardized 
stereoscopic seven-field fundus photographs of the DCCT/EDIC population and 
a probability model, they concluded that the screening schedule can be individu-
ally adapted to the state of retinopathy and HbA1c value (38). 
Retinal vascular geometry in children and adolescents with type 1 diabetes gained 
more attention. Retinal arteriolar and venular calibre, retinal vascular fractal di-
mension and arteriolar and venular tortuosity at baseline were shown to associ-
ate with (different states of) retinopathy after a follow up period of up to 16 years 
(9, 39-41). Besides, baseline abnormalities of retinal vascular geometry are found 
to predict other microvascular complications than retinopathy (7-9, 39). In addi-
tion to retinal vascular geometry, the handheld fundus camera may be of interest 
as well because of its ease in use. Despite its shown accuracy and efficiency in 
vision-threatening diabetic retinopathy (42), to our knowledge no research has 
been done with regard to the detection of the early signs of retinopathy.  
Macrovascular complications
Between 2007 and 2018, the ‘state of the art’ consisted predominantly of extend-
ing the studies in the field of surrogate markers of macrovascular complications 
that were already investigated in 2007: carotid intima media thickness (cIMT), 
arterial endothelial function and arterial stiffness. The number of studies in chil-
dren and adolescents with type 1 diabetes for these markers increased consid-
erably. The same applied to ‘losing track of lipids’ e.g. the change of a low-risk or 
borderline-high-risk lipid level into a borderline-high-risk/high-risk lipid level or a 
high-risk level respectively. 
Several studies showed cIMT to be increased in young study population with type 
1 diabetes as compared with healthy peers (43-45). In addition, cIMT progres-
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sion was detected in high risk patients within only a short follow up period (43, 
46). However, a review of observational studies showed that cIMT is not always 
increased in pediatric patients with type 1 diabetes when compared with healthy 
controls (47), possibly due to small study populations, young age, a short duration 
of diabetes (and thus follow-up), wide reference ranges for cIMT in children and 
adolescents and heterogeneity in cIMT study protocols (47). Several studies ad-
dressed the question if measurement of the aortic IMT (aIMT), instead of cIMT, 
should be the main marker of interest since atherosclerosis is thought to start 
in the intima of the distal abdominal aorta (48). Indeed, aIMT was found to be 
increased in the children and adolescents with type 1 diabetes as compared with 
their peers, whereas cIMT was not or to a lesser degree (49-52). However, this 
parameter is more difficult to measure in case of increased tissue penetrance. 
Additionally, longer measurement duration (15 minutes) has been mentioned as 
another disadvantage of this method (50-52). 
Markers reflecting endothelial dysfunction and measuring endothelial dysfunc-
tion itself gained more attention. Marcovecchio showed the intercellular ad-
hesion molecule-1 (ICAM-1) and myeloperoxidase (MPO), both biomarkers of 
endothelial dysfunction in the blood, to be increased to a similar extent in a small 
study group of adolescents with obesity or type 1 diabetes compared with healthy 
adolescents (53). Flow-mediated dilation (FMD) of the brachial artery as a result 
of reactive hyperaemia after shear stress was measured by several investigators 
using different techniques in children and adolescents with type 1 diabetes. Scar-
amuzza measured FMD through a fingertip plethysmograph (54), whereas most 
others (52, 55-57) performed high resolution ultrasound of the brachial artery. 
Despite FMD being a non-invasive objective measure of endothelial function, 
the required conditions of measurement in a regulated room temperature (52, 
54, 55), the possible influence of acute hyperglycaemia on FMD (55, 58) and the 
absence of pediatric reference ranges, make its implementation in routine outpa-
tient care challenging.
Arterial stiffness in type 1 diabetes has been extensively studied in the period 
2007-2018. Several measures for arterial stiffness, such as small artery elasticity 
(SAE), pulse pressure (PP), pulse wave velocity (PWV), augmentation index 
(A175) and brachial distensibility (BrachD) have been studied. 
Benitez-Aquirre evaluated SAE and PP in young adults (27.5 yrs +/- 14.5 SD) with 
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type 1 diabetes with microvascular complications and without microvascular 
complications and healthy controls (59). The patients with complications showed 
an earlier SAE peak in life and a diminished mean SAE in (young) adulthood 
compared with the patients with type 1 diabetes without complications and the 
healthy controls (59). PP, in this study measured by diastolic pulse-wave analysis 
(PulseWave) and an automated Sphygmomanometer, showed a slight decrease 
with increasing age in all three groups (healthy controls, patients with type 1 dia-
betes with and without complications) until the age of approximately 30-40 years 
old and showed a slight increase beyond this age. This increase was found to be 
more pronounced in the patients with type 1 diabetes and complications com-
pared with the other two groups. In children with type 1 diabetes, PP (measured 
by sphygmomanometer or Dinamab) was increased compared with pediatric 
reference values of two large studies (60). Notably, in type 1 diabetes, PP was 
already higher than the reference range in infancy. Moreover, PP particularly 
increased during the first 4 years and then stabilized (60). Dabelea evaluated the 
course of PWV in adolescents with type 1 diabetes, starting with a measurement 
in adolescence and repeating the measurement approximately 5 years later (61); 
PWV had significantly increased, but comparison with reference values was ab-
sent. Obermannova and Shah did compare results with reference ranges (62, 63). 
Obermannova found no abnormal PWV in the adolescents with type 1 diabetes 
(median age 16 yr (IQR 14-17), median diabetes duration 9 yr (IQR 6-16)(62). In 
contrast, the SEARCH study (Shah) did find an elevated PWV and augmentation 
index (AI75) and a decreased brachial distensibility in patients with type 1 diabe-
tes when compared with healthy controls (63, 64). These patients had approxi-
mately the same age and diabetes duration as the Obermannova study-group or 
were even younger with a shorter diabetes duration (63, 64). Reference values for 
European children and adolescents have been determined for PWV (65), PP (66) 
and SAE (67). To our knowledge, reference values of augmentation index (A175) 
and a diminished brachial distensibility have not been established yet. Less accu-
rate measurement of PP and PWC have been suggested in case of a very young 
age and an increased waist circumference respectively (61, 62). 
In addition to the early studies of Maahs (68) and Edge (69), more recent studies 
support the concept of ‘losing track of lipids’ among children and adolescents 
with type 1 diabetes (70-72). Associations between predominantly the determi-
nants HbA1c and BMI and lipid dynamics were shown (68, 70, 71). Also, several 
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cross-sectional studies in this age-group with type 1 diabetes showed added 
value in risk stratification by extending the lipid profile (low-density lipoprotein 
cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, 
total cholesterol and triglycerides) with lipids such as apolipoprotein B and LDL-C 
particle size that are supposed to inform better about the atherogenicity (73-75). 
Additional risk factors and surrogate markers
Advanced glycation end products (AGEs) as surrogate marker for complications
AGE levels were examined non-invasively in the skin in several studies in the 
period 2007-2018. In most studies, AGE levels were determined by skin autoflu-
orescence (SAF) or skin intrinsic fluorescence (SIF) (76-79). In adults with type 1 
diabetes, several studies confirmed the associations between increased SAF/SIF 
and the prevalence of micro- and macrovascular complications that were already 
shown in earlier studies (76-78, 80, 81). In children and adolescents with type 1 
diabetes, SAF/SIF were shown to be increased in this age-group when compared 
with healthy controls (49, 82-84). However, only a few studies examined SAF/SIF 
with regard to early signs of micro- and macrovascular complications in this age-
group. Cho showed SAF to associate with retinopathy and a measure of heart 
rate variability, but not with peripheral nerve abnormalities and albumin excretion 
rate or glomerular filtration rate (2). Lilje showed SIF to associate with aortic inti-
ma media thickness (49). In both adults and children and adolescents with type 1 
diabetes, correlations between SAF/SIF and HbA1c were examined. Despite the 
assumption that SAF/SIF provides information about glycaemic control of the 
preceding years (85), conflicting results on the association between past HbA1c 
and SAF/SIF were shown (2, 76, 78, 79, 81, 86, 87). Moreover, increased SAF/SIF 
was already shown in children that were just recently (< 1 week) diagnosed with 
type 1 diabetes (83) and was shown to be present in a subgroup of patients with 
normal HbA1c levels (2, 79). 
C-peptide as additional risk factor for the development of complications
Baseline and stimulated c-peptide levels, reflecting residual beta cell activity, are 
shown to protect against development of microvascular complications and cer-
tain risk factors of macrovascular disease in the course of type 1 diabetes (88, 89). 
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Steffes and Panero not only showed higher c-peptide levels to be more protec-
tive, but also showed that the presence of even minimal c-peptide levels was 
more beneficial when compared with undetectable levels (depending on the 
assay used defined by 0.03 and 0.06 nmol/l respectively)(88, 89). With the study 
of Kuhtreiber that shows c-peptide levels as low as 0.011 nmol/l to associate with 
a reduced complication risk (90), and the study of Wang that presents an even 
more sensitive assay for c-peptide detection (2.5 pmol/l)(91), c-peptide measure-
ment for risk-stratification in patients with type 1 diabetes becomes a promising 
subject for future research. 
HbA1c- and glucose-variability as additional risk factor for the development  
of complications
HbA1c variability has been found to be a risk factor for the development of 
micro- and macrovascular complications in several studies (92-94). Neverthe-
less, not all studies find a clear association between HbA1c variability and com-
plications (95), possibly due to different measures of HbA1c variability between 
studies (95). Alternatively, the measure HbA1c variability may not be sensitive 
enough for looking into glycaemic fluctuations. Consequently, glucose variability 
has been proposed to be a better predictor. Derr and McCarter showed HbA1c 
to reflect predominantly the mean glucose levels and not glucose variability (96, 
97). In addition, it has been argued that glucose variability and not mean glucose 
is more detrimental with regard to the development of complications (98-102). 
Enhanced oxygen stress as a result of glucose variability, has been one of the sug-
gested causative factors in the pathogenesis of these complications. However, 
the existence of a (clear) link between glucose variability, micro- and macrovas-
cular complications and/or measures of oxygen stress has not been demonstrat-
ed yet (103-107). The use of different measuring methods for glucose variability 
was put forward as an explanation (108, 109). Continuous glucose monitoring 
might lead to diagnostic opportunities, however consensus about which method 
to use for the expression of glucose variability has still to be determined (110-112).
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